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Summary 
 
 
Accumulating evidence indicates that multiple factors, including genetic and 
environmental ones, contribute to dopaminergic neuron degeneration in Parkinson’s 
disease (PD) (de Lau and Breteler 2006;Schapira et al. 2009;Gupta et al. 2008). 
Particularly, alterations in mitochondrial functions (Banerjee et al. 2009;Abou-Sleiman 
et al. 2006) with an increased production of reactive oxygen species (ROS) have been 
associated with degeneration of midbrain dopaminergic neurons (Zhou et al. 2008).  
Increasing number of in vitro and in vivo studies demonstrated the efficacy of 
polyphenolic antioxidants to reduce or to block neuronal death occurring in the 
pathophysiology of some neurodegenerative disorders (Ramassamy 2006). Particularly, 
Resveratrol (3,4',5-trihydroxystilbene, RSV), a polyphenol primarily found in grapes 
and red wine, has attracted considerable interest as being a free radical scavenger and 
potent antioxidant that enhances the activities of a variety of antioxidant enzymes (Baur 
et al. 2006). Therefore, on the basis of these observations, using different approaches, 
the first aim of present study was to analyze neuroprotective effects of RSV in MPTP-
mouse model of PD, inducing death of dopaminergic neurons in the substantia nigra 
pars compacta (SNc), and in dopaminergic neuronal (cell lines SN4741) exposed to 
oxidative stress.  
In both these models we could show a significant neuroprotective effect of RSV 
on dopaminergic neurons. The investigation was also extent to mechanisms involved on 
neuroprotective effect of RSV. RSV enhanced the levels of the mitochondrial 
antioxidants, superoxide dismutases 2 (SOD2) and thioredoxin (Trx), and both the 
levels and activity of transcriptional coactivator of peroxisome proliferator-activated 
receptor-γ (PGC-1α). Results obtained revealed that the beneficial effect of RSV was 
dependent on its effects on PGC-1α. During the course of these experiments, both in 
vivo and in vitro (cell lines SN4741), we observed unexpectedly that RSV treatment 
leads to a strong increase of dopamine transporter (DAT) expression in the striatum 
only in female mice. Since RSV is a phytoestrogen with striking similarity to the 
synthetic estrogen diethylstilbestrol, we also showed that the effect of RSV on DAT 
expression involves estrogen receptor activation by RSV.  
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On the basis of results revealing an increased levels and activity of PGC-1α after 
treatment with RSV, as second aim of this work, the neuroprotective role of PGC-1α 
was explored in MPTP mouse model of Parkinson’s disease, using transgenic mice 
overexpressing PGC-1α (PGC1-tg). Transgenic mice overexpressing PGC-1α in DA 
neurons were protected against cell degeneration induced by MPTP treatments. The 
levels of the mitochondrial antioxidants, SOD2 and Trx2 were found increased in the 
SN of PGC-1α transgenic mice compared with wild-type animals. Likewise, the 
mitochondrial enzyme cytochrome c oxidase IV (COX IV) was also elevated in the 
transgenic mice compared to controls. The increase in protein levels in the PGC-1α 
transgenic mice was accompanied by an enhanced gene expression, as shown here for 
SOD2 and COX IV using RT-PCR. This shows that overexpression of PGC-1α leads to 
changes in gene expression for a particular set of proteins in the SN with a potentially 
protective function in cell stress. 
Taken together the findings of this work suggest that RSV shows a 
neuroprotective effects in dopaminergic neurons both in vitro and in vivo and the results 
reveal an important function of the PGC-1α signaling in DA neurons to combat 
oxidative stress; furthermore, it may be possible to modulate both the activity and levels 
of PGC-1α by RSV in neurons to increase neuronal viability and to treat oxidative stress 
on different neurological diseases including PD. 
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 Background 
 
 
 Involvement of oxidative stress in Neurodegenerative diseases  
Mammalian life depends upon oxygen as the final acceptor of electrons in 
mitochondrial electron transport for energy production; these reactions in turn produce 
ROS (Liu et al. 2002;Phillips et al. 2003), such as superoxide anions, hydrogen 
peroxide, hydroxyl radical, peroxy radicals, and reactive nitrogen species (RNS). While 
these reactive species are important for execution of physiological functions, a their 
excessive production is detrimental to cell membranes and can cause cell death (Loh et 
al. 2006). Biological systems have evolved with endogenous defense mechanisms to 
help protect against free radical-induced cell damage. Glutathione peroxidase, catalase, 
and SOD are antioxidant enzymes, which metabolize toxic oxidative intermediates 
(Fang et al. 2002). They require micronutrients as cofactors such as selenium, iron, 
copper, zinc, and manganese for optimum catalytic activity and effective antioxidant 
defence mechanisms (Halliwell and Gutteridge 1992;Halliwell 2001). The disturbance 
in the balance between the production of ROS, or free radicals and antioxidant defenses, 
which may lead to tissue injury, has been defined  "oxidative stress".  
The central nervous system (CNS) is especially vulnerable to oxidative stress 
because of brain’s high oxygen consumption, its abundant lipid content, and the relative 
paucity of antioxidant enzymes as compared with other tissues (Skaper et al. 
1999;Roediger and Armati 2003). Moreover, brain has a high ratio of membrane surface 
area to cytoplasmic ratio, extended axonal morphology prone to injury, and neuronal 
cells are non-replicating. ROS can increase the permeability of the blood brain barrier, 
alter tubulin formation, and inhibit the mitochondrial respiration. If unchecked, it can 
lead to a geometrically progressing lipid peroxidation. Evidence also indicate that ROS 
may stimulate extracellular release of excitatory aminoacids (Gilman et al. 
1993;Rasheed et al. 2010). Glutamate is the major excitatory aminoacid in the brain. It 
acts through various types of ionotropic receptors, the most significant being, NMDA 
receptors (Ross et al. 2011). There seems to be a bi-directional relationship between the 
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ROS production and release of excitatory aminoacids (Coyle and Puttfarcken 
1993;Alexandrova and Bochev 2005). Free radicals generated in the brain are also 
reported to influence gene expression, subsequently effecting apoptosis and neuronal 
death (Gilgun-Sherki et al. 2002;Gupta et al. 2003).  
There is substantial evidence that mitochondrial dysfunction and oxidative stress 
are a causative or at least ancillary factor in the pathogenesis of major 
neurodegenerative diseases, including PD, Alzheimer’s disease (AD), Huntington’s 
disease (HD) and amyotrophic lateral sclerosis (ALS) as well as in cases of stroke, 
trauma, and seizures (Beal et al. 2000;Ienco et al. 2011); moreover, oxidative stress is a 
common pathogenic mechanism underlying many major psychiatric disorders (Wang et 
al. 2009). Infact, the loss of the redox balance implies a loss of regulation of the 
inflammatory response, which then causes a reparative and self-limiting response 
(Floyd et al. 2011). This becomes a perpetual response, a vicious cycle, in which there 
is mitochondrial failure that leads to a lack of adenosine triphosphate (ATP), an increase 
in the state of oxidative stress, loss of regulation of inflammatory markers, blocking of 
antioxidant systems, inability to synthesize new proteins, disorders of the proteasome, 
accumulation of misfolded proteins and, the conformational change in key receptors 
involved in metabolism and cell signaling (Sevcsik et al. 2011). All of them, established 
slowly over time, can produce chronic degenerative diseases and neurodegenerative 
diseases as a manifestation of a series of alterations caused by multiple factors, 
including that of the establishment of a state of chronic-oxidative stress (Halliwell 
2006). 
 
 Role of oxidative stress in the pathogenesis of Parkinson’s disease (PD)  
Parkinson’s disease is a common adult-onset neurodegenerative disorder. PD is 
clinically characterized by the tetrad of motor manifestations of tremor, rigidity, 
slowness of voluntary movements, and poor balance (Fahn 2003). PD arises essentially 
as a sporadic condition, that is, in absence of any evidence of genetic linkage, but, in a 
handful of cases, it is inherited (Dauer and Przedborski 2003). These rare occurrences 
can be from a variety of genetic defects, such as mutations in α-synuclein 
(Polymeropoulos et al. 1997), parkin (Kitada et al. 1998), DJ1 (Bonifati et al. 2003), 
PINK1 (Valente et al. 2004), and LRRK2 (Zimprich et al. 2004;Paisan-Ruiz et al. 2004) 
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which are transmitted as either dominant or recessive Mendelian traits (Vila and 
Przedborski 2004). That being said, clinically both the sporadic and the familial forms 
of PD are almost indistinguishable and they share the same basic biochemical hallmark, 
that is, a profound deficit in brain dopamine. The reason for this reduction in brain 
dopamine is because all of the ascending dopaminergic pathways in the CNS 
degenerate, albeit to variable degrees (Hornykiewicz and Kish 1987). For instance, 
among these pathways, the nigrostriatal pathway-which is composed of dopaminergic 
neurons residing in the ventral midbrain nucleus, called the SN, and which projects 
upward to the striatum, is consistently the most severely affected. It is important to 
stress, however, that PD neurodegeneration is not restricted to the dopaminergic 
systems as widespread neuronal loss can be detected in other catecholaminergic and 
noncatecholaminergic nuclei (Braak et al. 1995;Braak et al. 1995). Thus, if the main 
motor manifestations of PD are likely linked to neurodegeneration in the dopaminergic 
systems, nonmotor manifestations of PD, such as pain, cognitive impairments, and 
constipation, are more likely linked to neurodegeneration in these nondopaminergic 
pathways.  
Two other prominent features of PD neuropathologies include the presence of 
intraneuronal proteinaceous inclusions, called Lewy bodies, which are insoluble protein 
aggregates mainly composed of α-synuclein, found within many of the spared neurons 
in nearly all affected brain areas (Shults 2006) and gliosis (Przedborski 2007).  
The etiology of PD is unknown; however it is believed to be due to one or more of 
the following: age, genetics and/or environmental factors such as pesticides (Miller et 
al. 2007). 1-methyl-4-phenyl- 1, 2, 3, 6-tetrahydropyridine (MPTP) is a chemical that is 
related to the opioid analgesic drugs. MPTP is oxidized by monoamine oxidase B 
(MAO-B) to form 1-methyl-4- phenyl-pyridinium ion (MPP+), which is taken up by 
dopaminergic neurons and leads to cell death. It has been reported (Langston et al. 
1984) that injections of MPTP in squirrel monkeys resulted in parkinsonism. However , 
oxidative stress has been hypothesized to be linked to both the initiation and the 
progression of PD. Preclinical findings from both in vitro and in vivo experimental 
models of PD suggest that the neurodegenerative process starts with otherwise healthy 
neurons being hit by some etiological factors, which sets into motion a cascade of 
deleterious events. In these models initial molecular alterations in degenerating 
dopaminergic neurons include increased formation of reactive oxygen species, 
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presumably originating from both inside and outside the mitochondria (Zhou et al. 
2008).  
A number of studies have searched for indices of oxidative stress in autopsy 
materials obtained from PD patients. These markers come in different flavors since 
ROS and RNS can damage virtually all biological macromolecules. First oxidative 
metabolism of dopamine itself (Graham et al. 1978) exposes dopaminergic neurons of 
the SNc to chronic oxidative stress compared to other regions of the brain. Dopamine as 
a neurotransmitter is stable in the synaptic vesicle, but when an excess amount of 
cytosolic dopamine exists outside of the synaptic vesicle in the damaged neurons, 
dopamine is easily metabolized via MAO or by auto-oxidation to produce cytotoxic 
ROS (Sulzer et al. 2000). In the oxidation of dopamine by MAO, H2O2 and 
dihydroxyphenylacetic acid (DOPAC) are generated. In contrast, non-enzymatical and 
spontaneous auto-oxidation of dopamine produces O2- and reactive quinones (Graham 
1978). Generated O2- is converted to H2O2 by SOD and O2- also reacts with nitric oxide 
radicals (NO.) to consequently generate peroxynitrite. In the dopaminergic neurons, 
where metals are abundant, H2O2 can react with metals, especially iron, to form the 
most cytotoxic radical (OH). Enzymatic oxidation of dopamine to H2O2 causes also 
increased formation of oxidized glutathione, suggesting the occurrence of oxidative 
stress and impairment of a major antioxidant system (Spina and Cohen 1988).  
Mitochondrial dysfunction is also an intrinsic aspect of an oxidative stress 
hypothesis due to their major role in the production of cellular ROS. Consistent deficits 
in the subunits and activity of mitochondrial complex I (NADH ubiquinone 
Oxidoreductase) of the electron transport chain in blood platelets and SNc of PD 
patients is a prominent phenomenon (Keeney et al. 2006;Beal 2005), suggesting central 
role of mitochondrial dysfunction in PD. A recent study demonstrated that SNc neurons 
have high amount of mitochondrial DNA (mtDNA) deletions in postmortem PD 
patients when compared with other neuronal populations in brain- and age-matched 
controls (Bender et al. 2006). A related study identified that nigral neurons from PD 
patients contain high levels of clonally expanded somatic mtDNA deletions leading to 
mitochondrial dysfunction (Kraytsberg et al. 2006). Also a decrease in the function of 
Complex III has also been reported in the lymphocytes and platelets of PD patients 
(Shinde and Pasupathy 2006). Studies of families who suffer from inherited forms of 
PD have identified a number of genes encoding mitochondrial proteins or proteins 
implicated in mitochondrial dysfunction (Oakley et al. 2007). Moreover, mitochondrial 
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DNA is particularly susceptible to oxidative damage, because of its vicinity with ROS 
source (electron transport chain) and because it is not protected by histones and is 
inefficiently repaired. Furthermore, NO accumulation can form adducts with 
mitochondrial enzymes and dysregulate mitochondrial function (Ebadi and Sharma 
2003;Yamamoto et al. 2007).  
Recent studies suggest that also Endoplasmatic Reticulum stress by accumulation 
of unfolded and/or misfolded proteins contribute to PD (Wang and Takahashi 2007). 
Finally, inflammation can also contribute to ROS production and has been implicated in 
the pathogenesis of PD; infact, activation of microglia in response to injury is associated 
with an upregulation of inducible nitric oxide synthase (iNOS) resulting in increased 
production of NO (Drechsel and Patel 2008). 
 
Oxidative stress in MPTP model of PD 
Animal models are an invaluable tool for studying the pathogenesis and therapeutic 
intervention strategies of PD by toxin-induced Parkinsonism. Infact, there is extensive 
evidence that PD can be caused by neurotoxins, specifically MPTP (Davis et al. 1979), 
rotenone (Greenamyre et al. 1999), paraquat (Liou et al. 1997), diquat (Sechi et al. 
1992), and 1-Trichloromethyl-1,2,3,4-tetrahydro-β-carboline (TaClo) (Bringmann et al. 
1995a;Bringmann et al. 1995b). These compounds are thought to act via various 
mechanisms, but all by causing mitochondrial dysfunction. To date, MPTP remains the 
best characterized PD model and has provided the strongest support for the role of 
oxidative stress in disease pathogenesis. MPTP is a by-product of the chemical 
synthesis of a meperidine analog with potent heroin-like effects (Langston and Irwin 
1986). 
In humans and non-human primates, depending on the regimen used, MPTP can 
produce an irreversible and severe parkinsonian syndrome that replicates almost all of 
the features of PD, including tremor, rigidity, slowness of movement, postural 
instability, and even freezing (Przedborski et al. 2001). The most frequently used 
animals for MPTP studies are monkeys, mice and rats. The administration of MPTP 
through a number of different routes using different dosing regimens has led to the 
development of several distinct models, each characterized by some unique behavioral 
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and/or biochemical features. MPTP is a lipophilic protoxin that readily crosses the 
blood brain barrier and is converted to MPP+ by MAO-B in astrocytes (Nicklas et al. 
1985). Subsequently, MPP+ produced is then released from astrocytes and taken up by 
dopaminergic neurons (Schober 2004) by binding to DAT with high affinity (fig. 1) and 
accumulated to high levels in mitochondria where MPP+ inhibits mitochondrial 
Complex I (NADH quinone oxidoreductase) (fig. 2) (Nicklas et al. 1987). This 
inhibition of Complex I leads to cell death via energy deficits (Przedborski et al. 2000), 
free radical and ROS generation (Cleeter et al. 1992) and possibly excitotoxicity 
(Bezard et al. 2006). Inside neurons, MPP+ can also bind to the vesicular monoamine 
transporter-2 (VMAT2), which translocates MPP+ into synaptosomal vesicles (Schober 
2004). This uptake system serves as a detoxification mechanism and mice with 
depletion of vesicular monoamine transporters are more sensitive to MPP+ toxicity 
(Schober 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig. 1- Schematic MPTP metabolism in the 
    nigrostriatal system. 
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Studies have shown that MPP+ can also directly inhibit complexes III (ubiquinol: 
ferrocytochrome c oxidoreductase) and IV (ferrocytochrome c: oxygen oxidoreductase 
or cytochrome c oxidase) of the electron transport chain (Mazzio and Soliman 2004). 
This leads to impairment of ATP production, elevated intracellular calcium levels, and 
free radical generation, thereby exhibiting dopaminergic neurotoxicity (Yokoyama et al. 
2008). MPTP administration has been shown to be more efficient at killing dopamine 
neurons in mice than rats, despite greater MPP+ formation and uptake in rat striatum 
(Guillot and Miller 2009). 
 
 
Fig. 2- Schematic representation of MPP+ intracellular pathways. 
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Neuroprotective strategies against oxidative stress in PD 
During the last few decades, there has been a remarkable progress in the 
understanding of the biology of PD, which has been translated into the development of 
numerous antiparkinsonian drugs. There are different therapeutic strategies for patients 
in an early stage versus patients in a late stage of the disease. The approach with 
dopamine precursor treatment in the form of L-dopa, represents the backbone of 
therapy. Although levodopa is considered the gold standard for treatment of PD, 
multiple complications such as motor fluctuations, hallucinations, and psychosis arise 
from long-term therapy (Olanow 2002;Jankovic 2002). For this reason, new 
neuroprotective strategies are needed and controlled clinical trials are focused on agents 
that combat excitotoxicity, counteract inflammation, provide trophic factors, inhibit 
apoptosis, reduce oxidative stress, and enhance mitochondria function (Ginsberg 2008). 
These new approaches includes antiapoptotic drugs, pro-mitochondrial drugs and 
antioxidant drugs (Schapira 2008). 
Antiapoptotic drugs: Apoptosis is considered to be an important cause of cell 
death in PD. The known genetic causes of PD and the toxins that induce dopaminergic 
cell death all mediate neuronal loss via apoptosis, although this may not be the only 
mechanism by which they act. Drugs that block apoptosis, therefore, seem to be good 
candidates for trials in PD. Selegiline, a selective irreversible MAO-B inhibitor, can 
protect cultured dopaminergic neurons against the MPP+ and in animal models can 
reduce dopaminergic cell loss in response to MPTP (Mytilineou and Cohen 1985;Wu et 
al. 2000). Selegiline also protects against apoptotic cell death induced by serum and 
growth factor withdrawal (Palhagen et al. 2006), possibly via an increased production of 
Bcl-2. Selegiline, by virtue of its MAO-B inhibitory activity will reduce the turnover of 
dopamine and so reduce free radical generation. Rasagiline is a more potent MAO-B 
inhibitor than selegiline and has also demonstrated protective effects against a wide 
range of neurotoxins both in vitro and in vivo studies. For instance, it protects against 
MPTP/MPP+ and 6-hydroxydopamine (6-OHDA) toxicity and excitotoxic-mediated 
damage, and stabilizes the mitochondrial membrane potential to reduce apoptotic cell 
death (Akao et al. 2002;Bar et al. 2004). Rasagiline has an advantage over selegiline in 
that both the parent compound and the aminoindan metabolite have neuroprotective 
actions, while selegiline-mediated neuroprotection appears to depend on its desmethyl 
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metabolite. Furthermore, selegiline is metabolized to metamphetamine, a compound 
which itself has neurotoxic effects and which also blocks the protective action of 
rasagiline, aminoindan and selegiline. The isomer of rasagiline devoid of MAO-B 
inhibitory activity is also active in laboratory neuroprotective studies, indicating that 
this property is independent of MAO-B inhibition (Youdim et al. 2001). Another 
antiapoptotic drugs is the TCH346 that incorporates a propargyl ring within its 
molecular structure and so resembles selegiline. However, as it does not inhibit MAO-
B, it was not anticipated to have symptomatic effects in clinical trials. Like other 
propargylamines (Schapira et al. 2005), TCH346 has been shown to prevent death of 
dopamine neurons in various in vitro models of apoptosis (Carlile et al. 
2000;Waldmeier et al. 2000) and to protect against behavioural abnormalities and 
neurodegeneration in animal models of PD; infact, TCH346 have been shown to prevent 
the stress-induced translocation of the glycolytic enzyme glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) from the cytoplasm to the nucleus where it promotes nerve 
cell death by blocking the transcriptional upregulation of protective molecules such as 
Bcl-2 and SOD (Carlile et al. 2000;Tatton et al. 2002). 
Promitochondrial drugs: The recognition that mitochondrial dysfunction plays a 
role in PD pathogenesis provided a rationale to test the hypothesis that drugs that 
improve mitochondrial function might slow the progression of the disease (Schapira 
2007). The first of these studies used coenzyme Q10 (CoQ10) which functions as both a 
component of the respiratory chain in shuttling electrons between complexes I and III, 
and as an antioxidant. Creatine is another treatment investigated for potential disease-
modifying effect based upon the evidence for mitochondrial dysfunction in PD. 
Creatine is converted to phosphocreatine and can transfer a phosphoryl group to ADP to 
synthesize ATP and so enhance energy production. Creatine can reduce dopaminergic 
cell loss in  the MPTP rodent model of PD (Matthews et al. 1999). One key set of genes 
dysfunctional in the brains of Parkinson’s patients is controlled by the master switch 
PGC-1α. PGC-1α activates mitochondrial genes, including many of those needed to 
maintain and repair the power plants in the mitochondria. Reduced expression of the 
genes that PGC-1α regulates likely occurs during the initial stages of PD, perhaps even 
before the onset of symptoms. The researchers then showed that PGC-1α can be used as 
a “power switch” to turn on the expression of the energy genes-which are deactivated in 
patients with Parkinson’s - in cell models of the disease (Zheng et al. 2010). 
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Antioxidant drugs: Dopamine agonists have a hydroxylated benzyl ring structure 
and so may have natural activity as free radical scavengers. Several dopamine agonists 
have demonstrated antioxidant activity in different in vitro systems. For instance, 
apomorphine scavenges free radicals from isolated rat brain mitochondria (Gassen et al. 
1996) and can also reduce iron (Ubeda et al. 1993). Bromocriptine protects mice against 
6-OHDA and MPTP-induced cell loss and attenuates dopamine depletion in mouse 
striatum in response to methamphetamine (Ogawa et al. 1994). Cabergoline decreased 
lipid peroxidation in rat striatum (Finotti et al. 2000) and also protected against 6-
OHDA toxicity in mice (Yoshioka et al. 2002). Pramipexole and pergolide scavenge 
hydroxyl superoxide and nitric oxide radicals (Gomez-Vargas et al. 1998) and pergolide 
upregulates SOD in basal ganglia (Clow et al. 1993). Ropinirole increases the 
concentration of glutathione, catalase and SOD (Iida et al. 1999). Although there is 
good evidence that agonists may function as free radical scavengers, the concentration 
required for them to have this activity is probably higher than levels that might be 
achieved by oral administration. 
Recently, we have been examining the neuroprotective effects of flavonoids 
which are powerful antioxidants, able to chelate metal ions as iron and have been shown 
in-vitro to boost cellular anti-oxidant levels. Although flavonoids are present in our diet, 
they are generally found in the parts of fruits that we throw away like the pith, peel and 
the core. Hence, flavonoids seem ideal agents to test as neuroprotective agents in PD 
(Soobrattee et al. 2005). Studies indicate that moderate amounts of wine, rich in 
polyphenolic compounds, can prevent the formation of free radicals, and then be used in 
the treatment of neurological diseases as Parkinson (Arvanitoyannis and Giakoundis 
2006). 
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Antioxidative effects of RSV against oxidative stress 
Increasing number of in vitro and in vivo studies demonstrated the efficacy of 
polyphenolic antioxidants to reduce or to block neuronal death occurring in the 
pathophysiology of some neurodegenerative disorders (Ramassamy 2006). Polyphenols 
are natural substances that are present in plants, fruits, and vegetables, including olive 
oil, red wine, and tea. Tea polyphenols have been found to be potent scavengers of 
singlet oxygen, superoxide anions, hydroxyl radicals and peroxyl radicals (Morel et al. 
1993;Nanjo et al. 1996) and consumption of tea has beneficial role in reducing risk of 
PD (Checkoway et al. 2002). Among polyphenolic compounds, numerous phytoalexins 
have been tested for their putative therapeutic functions either in vitro and in vivo 
experimental models and particular accumulating number of evidence suggests that 
RSV might possess a clinical usefulness (Pezzuto 2004).  
RSV has been classified as a phytoalexin with a stilbene structure (fig. 3), for 
being synthesized in spermatophytes in response to injury, UV irradiation, and fungal 
attack (Ignatowicz and Baer-Dubowska 2001). It is present in a wide variety of dietary 
sources including grapes, plums and peanuts, but also in wines, especially red wines and 
to a much lesser extent in white wines. RSV is a phytoestrogen with striking similarity 
to the synthetic estrogen diethylstilbestrol, and available data suggests that RSV may be 
an estrogen receptors (ERs) agonist (Gehm et al. 1997) that bind to both ERα- and ERβ 
(Bowers et al. 2000;Mueller et al. 2004;Robb and Stuart 2011;Wu et al. 2008). RSV 
exists as cis- and trans-isomers. Trans-RSV is the preferred steric form and is relatively 
stable if it is protected from high pH and light. One of the biological activities that has 
been ascribed to RSV involves its antioxidant potential (fig. 4). The ability of the 
polyphenolic compounds to act as antioxidants depends on the redox properties of their 
phenolic hydroxy groups and the potential for electron delocalization across the 
chemical structure (Martin et al. 2006). 
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  Fig. 4- Intracellular oxidative stress and potential    
antioxidant action sites of RSV. 
 
 
Fig. 3- Chemical structure of RSV. 
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The common recognition of RSV as a natural antioxidant was clarified by Zini et 
al. (Zini et al. 1999), who suggested three different antioxidant mechanisms: (i) 
competition with coenzyme Q and, to decrease the oxidative chain complex, the site of 
ROS generation; (ii) scavenging O2.- radicals formed in the mitochondria; (iii) inhibition 
of lipid peroxidation. According, numerous studies have demonstrated the ability of 
RSV to scavenge both O2.- and .OH radicals (fig. 4) (Leonard et al. 2003;Losa 
2003;Martinez and Moreno 2000). However, RSV is both a free radical scavenger and a 
potent antioxidant because of its ability to promote the activities of a variety of 
antioxidant enzymes. In this context, RSV can increase the amounts of several 
antioxidant enzymes, including glutathione peroxidase, glutathione S-transferase and 
glutathione reductase (Yen et al. 2003).  
Recent studies seem to support also pro-oxidant activities of RSV, depending on 
its concentration and the cell type. For example pro-oxidant action of RSV leading to 
oxidative breakage of cellular DNA has been proposed as action mechanism of its 
anticancer and apoptotic properties (de la Lastra and Villegas 2005). In a recent work 
the connection between RSV and oxidative stress in PC6.3 cells (a neuron-like cell line 
from the peripheral nervous system) has been investigated. Data showed that RSV at 
lower concentrations had a beneficial effect in PC6.3 cells, counteracting oxidative 
stress and increasing cell viability. Treatment with RSV increased levels of 
mitochondrial antioxidants and activated NF-kB signaling that may contribute to cell 
protection (Kairisalo et al. 2011). 
 
Role of RSV in Neuroprotection and in Neurodegenerative diseases treatment 
The natural phytocompound RSV has been considered for many years a potential 
anticancer drug, but recently it has come to the attention of neuroscientist too. Infact, 
RSV has neuroprotective features both in vitro and in vivo in models of AD, ischemic 
stroke, epilepsy, HD and PD (Albani et al. 2010). The AMP-activated protein kinase 
(AMPK), sirtuin 1 (SIRT1), and PGC-1α were all thought to be involved in the etiology 
of these neurological disorders. Based on evidence that RSV modulates these proteins, 
it was proposed that RSV has therapeutic potential in the above-mentioned 
neurodegenerative disease (Canto and Auwerx 2009;Um et al. 2010;Vingtdeux et al. 
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2010). SIRT1 appears to be required for RSV metabolic functions in vivo by 
contributing to an energy sensing network involving AMPK and PGC-1α (Canto and 
Auwerx 2009;Ruderman et al. 2010).  
Consistent observations have demonstrated that moderate red wine consumption 
beneficially modulates AD-type cognitive deterioration in the Tg2576 transgenic mouse 
model of AD by attenuating Aβ neuropathology (Wang et al. 2006;Ho et al. 2009). 
Importantly, Kim and colleagues (Kim et al. 2007) recently reported that 
intracerebroventricular injection of RSV reduced neurodegeneration in the hippocampus 
and prevented learning impairment in the p25 transgenic AD mouse model by a 
mechanism that may involve a decrease in the acetylation of known SIRT1 substrates, 
for example, PGC-1α and p53. The scientists have been exploring the ability of RSV to 
provide neuroprotection against ischemic attack. A recent study revealed that RSV, 
selectively induces heme oxygenase 1 (HO1) in a dose- and time-dependent manner in 
cultured mouse cortical neuronal cells and provides neuroprotection from free-radical or 
excitotoxicity damage. These data suggest a potential intracellular pathway by which 
RSV can provide cell/organ resistance against neuropathological conditions in ischemic 
stroke (Sakata et al. 2010). Moreover, laboratory animals given intraperitoneal 
injections of RSV showed less motor impairment and significantly smaller infarct 
volume, together with decreased delayed neuronal cell death and glial cell activation 
after ischemia (Raval et al. 2008). There are also some clear evidences that RSV 
decreased the frequency of spontaneous seizures and inhibited the epileptiform 
discharges. Moreover, RSV could protect neurons against kainate-induced neuronal cell 
death in CA1 and CA3a regions and depressed mossy fiber sprouting, which are general 
histological characteristics both in temporal lobe epilepsy patients and animal models 
(Wu et al. 2009). The authors showed the in vitro efficacy of RSV to protect against 
mutant polyglutamine-mediated cell death in striatal neuronal cultures isolated from the 
HdhQ111 knock-in mice model of HD (Parker et al. 2005). In addition, the authors also 
demonstrated RSV may neuroprotect HdhQ111 striatal neuron cultures through 
promotion of SIRT1-related mechanisms. Recent evidence suggests that PGC-1α 
deregulation may be essential in the pathogenesis of HD (Chaturvedi et al. 2010;McGill 
and Beal 2006).  
Based on this, together with in vitro evidence that RSV promotes SIRT-1 
deacetylase activity (Howitz et al. 2003) and additional in vitro studies suggesting that 
RSV may protect against HD-type neurotoxicity. Previous in vivo studies suggest that 
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RSV exerts beneficial effects in experimental models of PD (Chao et al. 2008). For 
example, the administration of a diet containing RSV or treatment with RSV to adult 
mice prior to treatment with the neurotoxin MPTP exerts neuroprotective effects on 
dopaminergic neurons (Blanchet et al. 2008;Lu et al. 2008). Furthermore, RSV is known 
to protect neuronal cells against MPP+- induced oxidative stress and cellular death in 
vitro (Gelinas and Martinoli 2002;Okawara et al. 2007). Jin et al have showed that RSV 
treatment significantly counteracts SNc neuronal death in rats treated with 6-OHDA by 
reducing inflammatory reaction (Jin et al. 2008). Accordingly, RSV could be an 
interesting candidate for potential application in the treatment of PD; at present it 
remains to be clarified if RSV could activates SIRT1 and offers neuroprotection in PD 
(Pallas et al. 2009).  
In some work has also been hypothesized that the neuroprotective effect of RSV 
in Parkinson's disease, may be linked to its ability to act as a phytoestrogen; infact, RSV 
can mimic the action of Ers agonist (Gehm et al. 1997;Bowers et al. 2000) and this has a 
correlation with the information that the PD is almost twice as common in men as in 
women (Shulman 2007). Therefore researchers have long hypothesized that sex 
hormones might play a role in the disease (Gelinas and Martinoli 2002;Pozzi et al. 
2006). Infact, currently in the research community, there is much interest in the 
possibility of using estrogen to either slow the progression or reduce the risk of PD 
(Shulman 2007). 
 
PGC-1α play an important role in Neurodegenerative diseases 
Recent studies indicate that maintenance of mitochondrial function is beneficial in 
the prevention or delay of neurodegenerative diseases. A central molecule seems to be 
the PGC-1α, which is the key regulator of mitochondrial biogenesis and oxidative 
metabolism (Lin et al. 2004;Tyynismaa et al. 2010). The transcriptional coactivator 
PPARGC1A (PGC-1α) gene is located on chromosome 5 in mice (chromosome 4 in 
humans) and encodes a protein containing 797 (mouse) or 798 (human) amino acids 
(Puigserver et al. 1998). PGC-1α belongs to a small family of transcriptional 
coactivators, including PGC-1β and PGC-1-related coactivator (PRC), which possess a 
common function in mitochondrial physiology, in addition to control over separate 
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specific biological programs. PGC-1α was the first member identified as a cofactor for 
the nuclear hormone receptor PPARγ that is required for the adaptive thermogenic 
response to lower temperatures (Puigserver et al. 1998;Puigserver et al. 1999).  
PGC-1α as a transcriptional coactivator functions through direct physical 
interaction with transcription factors directly bound to DNA promoter regions. 
Structural and functional studies have indicated that PGC-1α has a strong transcriptional 
activation domain at the N-terminus, which interacts with several histone 
acetyltransferase complexes including 3’-5’-cyclic adenosine monophosphate (cAMP) 
response element-binding protein (CREB)-binding protein, p300, and steroid receptor 
coactivator-1 (fig. 5)  (Puigserver et al. 1999). These proteins acetylate histones and 
remodel chromatin structure into a state that is permissive for transcriptional activation. 
Adjacent to the N-terminal domain is a regulatory region that roughly spans 200 amino 
acids. Toward the C-terminus, PGC-1α recruits the thyroid receptor-associated 
protein/vitamin D receptor interacting protein/mediator complex that facilitates direct 
interaction with the transcription initiation machinery (Wallberg et al. 2003). The 
Ser/Arg-rich domain and an RNA-binding domain toward C-terminus have been 
demonstrated to couple pre-mRNA splicing with transcription (fig. 5) (Monsalve et al. 
2000). 
 
 
 
  
Fig. 5- Architecture of the PGC-1α transcriptional coactivator. PGC-1α 
contains several functional domains that correlate with the 
interactions with different proteins and complexes. 
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As such, PGC-1α serves as a platform for the recruitment and assembly of various 
chromatin remodeling and histone-modifying enzymes to alter local chromatin state. 
Importantly, the PGC-1α transcriptional activator complex is also able to displace 
repressor proteins, such as histone deacetylase and small heterodimer partner, on its 
target promoters, providing an alternative mechanism for gene activation (Borgius et al. 
2002). PGC-1α and PGC-1β share extensive domain similarity and several clusters of 
conserved amino acids, such as the LXXLL motif that interacts with nuclear receptors 
and host cell factor 1 interacting motif (Lin et al. 2003). The third family member, PRC, 
also contains the activation domain and RNA-binding domain, but overall has more 
limited homology to PGC-1α and PGC-1β (Andersson and Scarpulla 2001). PGC-1α 
contains specific phosphorylated, acetylated and methylated amino acids which can 
modulate its activity as well as interaction with other proteins including corepressors 
(Lerin et al. 2006). An important regulatory mechanism of PGC-1α is through SIRT1-
mediated lysine de-acetylation. Moreover, SIRT-1 activation will maintain PGC-1α in a 
deacetylated active form bound to the chromatin and increasing rates of transcription 
(Rodgers et al. 2005;Gerhart-Hines et al. 2007).  
PGC-1α is abundantly expressed in tissues with high energy demand, including 
the brown adipose tissue (BAT), heart, skeletal muscle, kidney, liver and brain (fig. 6) 
(Wu et al. 1999;Knutti et al. 2000). Infact, when ectopically expressed in fat or muscle 
cells, PGC-1α strongly stimulates the program of nuclear and mitochondrial-encoded 
mitochondrial genes as well as organelle biogenesis (Wu et al. 1999). The stimulatory 
effects of PGC-1α on mitochondrial genes are achieved through its coactivation of 
nuclear respiratory factors 1 and 2 (NRF1 and NRF2, respectively) and the estrogen-
related receptor a (ERRa) (fig. 6) (Mootha et al. 2004;Schreiber et al. 2004). 
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The induction of NRF1 and NRF2 subsequently leads to the increased expression 
of mitochondrial transcription factor A (mtTFA) (Wu et al. 1999) as well as other 
mitochondrial subunits of the electron transport chain complex such as ATP synthase, 
cytochrome c, and COXIV (Scarpulla 2002a;Scarpulla 2002b). mtTFA translocates to 
mitochondrial matrix, where it stimulates mitochondrial DNA replication and 
mitochondrial gene expression (Larsson et al. 1998). The brain constitutes perhaps the 
most vulnerable tissue to oxidative stress. Impaired PGC-1α expression and 
mitochondrial function contributes to neurodegeneration in susceptible neurons (Weydt 
et al. 2006). In addition, PGC-1α plays an important role in the regulation of genes 
responsible for the detoxification of ROS, including copper/zinc SOD1, manganese 
SOD2, and glutathione peroxidase 1 (St-Pierre et al. 2006). Interestingly, SIRT-1 plays 
a similar role in oxidative stress function in combination with FoxO transcription 
factors (Brunet et al. 2004). For this reason, PGC-1α plays an important role in normal 
brain function and a major role in the oxidative stress response (St-Pierre et al. 2006).  
In mice, PGC-1α deficiency causes behavioral changes including anxiety and 
hyperactivity as well as hind limb clasping. These behavioral changes are associated 
with spongiform-like vacuolization primarily in the striatum associated with gliosis and 
leads to reduced expression of several brain-specific genes that are all associated with 
 Fig. 6- Schematic representation of the different fuctions of PGC-1α in its    
target tissues. 
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normal brain function (Lin et al. 2004). SN and CA1 neurons are more susceptible to 
neurodegeneration in response to neurotoxins suggesting an important role of PGC-1α 
in neuronal maintenance (Lin et al. 2004). PGC-1α also seems to be involved in the 
control of neurite growth and neuronal synaptic function (Cowell et al. 2009). PGC-1α 
has been implicated in the onset and progression of neurodegenerative diseases. 
Postmortem brain samples of patients with HD had a decreased level of PGC-1α mRNA 
(Cui et al. 2006;Weydt et al. 2006). PGC-1α is repressed by a mutant form of the 
Huntington protein which leads to mitochondrial dysfunction and neurodegeneration. 
Over-expression of PGC-1α rescues cells from the deleterious effect of HD, whereas 
loss of PGC-1α in HD mice aggravated neurodegeneration (Cui et al. 2006). Moreover, 
PGC-1α KO mice show HD like phenotype and neuronal lesions suggesting that PGC-
1α is crucial for maintenance of striatal function. Additionally, PGC-1α SNPs are 
associated with the age of onset of HD. Polymorphismis are also associated with the 
onset of AD (Qin et al. 2009). In a PD mouse model, PGC-1α deficiency caused an 
increased degeneration of dopaminergic neurons in the SN associated with oxidative 
damage (St-Pierre et al. 2006;Bender et al. 2006).  
Interestingly, activators of PGC-1α such as RSV have a neuroprotective effect in 
acute and chronic brain injury as well as in neurodegenerative diseases suggesting a role 
for PGC-1α in modulating the outcome of the disease (Sun et al. 2010). In addition, 
studies with mice treated with RSV and ectopic expression of SIRT1 (that correlated 
with deacetylation of PGC-1α) in the hippocampus further support the neuroprotective 
role of SIRT1 in AD and ALS (Kim et al. 2007). Together, these studies suggest that 
PGC-1α and SIRT1 might be potential targets to treat neurodegenerative diseases. 
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Aims 
 
 
Aim 1  
The aim 1 of present work was to study the neuroprotective effect of RSV against 
oxidative stress using both in vivo and in vitro models. To this end, we evaluated 
neuroprotective effects of RSV in MPTP-mouse model of PD, inducing death of 
dopaminergic neurons in the SN and in dopaminergic neuronal cell lines SN4741 exposed 
to oxidative stress. Additionally, in order to identify the possible “neuroprotective 
signaling” involved in the effect of RSV, the investigation was also extent to evaluation of 
RSV effect on expression of SOD2 and Trx2 and on the activity and the levels of 
transcriptional coactivator PGC-1α that is a master regulator of cell metabolism, 
mitochondrial biogenesis, oxidative stress and gene expression.  
 
Aim 2 
The aim 2 of present work was to explore the neuroprotective role of PGC-1α in 
MPTP mouse model of PD, using transgenic mice overexpressing PGC-1α (PGC1-tg).  
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Materials and methods 
 
 
Animals 
Adult male and female C57/BL6 mice (25-28 g b.w.) from local stock have been 
used for the present study. The mice were kept under environmentally controlled 
conditions, ambient temperature 24°C, humidity 40% and 12-h light/dark cycle with food 
and water ad libitum. Procedures involving animals and their care were conducted in 
conformity with the institutional guidelines that are in compliance with national (D.L. n. 
116,G.U., suppl. 40, 18 Feb. 1992) and international laws and policies (EEC Council 
Directive 86/609, OJ L 358,1, Dec. 12,1987; NIH Guide for the Care and Use of 
Laboratory Animals, NIH Publication no. 80-23, 1985 and Guidelines for the Use of 
Animals in Biomedical Research, Thromb. Haemost. 58, 1078–1084,1987). All efforts 
were made to minimize the number of animals used and their suffering and all experiments 
were approved by the local ethical committee. 
 
Generation of PGC-1α transgenic mice 
The PGC-1α cDNA with a Flag-tag was cloned into the Thy 1.2 expression cassette 
that drives transgene expression in brain neurons (Caroni 1997;Trapp et al. 2003). 
Transgenic mice were generated using standard techniques at the Uppsala Transgenic 
Facility, at Uppsala University, Sweden. The genetic background of the mice was CBA × 
C57BL/6 and they were backcrossed to C57BL/6 mice for several generations to produce 
stable PGC-1α transgenic mouse lines, and controls were from the same breeding. The 
levels of PGC-1α in brain tissue including SN and striatum were studied by 
immunoblotting and using a polyclonal anti-PGC-1α antibody raised in rabbit against the 
amino acids 221–234 in the mouse sequence. Immunoblots were done as described below. 
dott.sa Melania Olivieri 
22 
To analyze the transgenic expression of PGC1 in dopaminergic neurons, 
immunostaining in SN was done using anti- Flag antibodies (1:300; Cell Signaling) in 
combination with anti-TH antibodies and employing appropriate fluorescent- labeled 
secondary antibodies. The mice showed expression of the PGC-1α transgene in 
dopaminergic neurons. Apart from midbrain, the transgene was expressed in other brain 
regions (data not shown), and a thorough characterization of gene expression in the PGC-
1α transgenic mice will be reported later. 
 
Drug treatments 
All experiments were approved by the local ethical committee and performed in 
accordance with the European Communities Council Directive (86/609/EEC). Mice 
received three intraperitoneal (i.p.) injections of 14 mg/kg MPTP (Fluka Biochemica) 
within a time period of 3 h followed by a fourth injection using 7 mg/kg MPTP. This 
protocol induced a lesion of TH-positive neurons in the SNc with a low degree of mortality 
of animals. Twenty mg/kg RSV (R5010 Sigma) was dissolved in 50% DMSO/70% ethanol 
and diluted in saline until to a final volume of 0.2 ml per mice and given i.p. Control mice 
received vehicle 50% (DMSO/70% ethanol diluted in saline) only. All mice were killed 7 
days after the MPTP treatment using deep anesthesia and their brains were collected for 
immunohistochemistry or Western-blot analysis.  
To verify the involvement of estrogen receptors on RSV-enhanced DAT expression, 
groups of mice were treated with the antiestrogen ICI 182,780 also known as Fulvestrant 
(Tocris Bioscience, Bristol, UK; cat. no. 1047). ICI 182,780 was used at dose of 2 mg/kg 
b.w., and was dissolved first in absolute ethanol and thereafter diluted in sesame oil and 
injected subcutaneously in 50 ml. Mice were treated with RSV or antiestrogens according 
to injection scheme described in results section. Control mice received an equal volume of 
vehicle. Mice were killed under deep anesthesia. 
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Immunohistochemistry 
Cell counting and measurements of fiber densities as described below were all 
carried out in a double-blind manner. To compare experimental groups, the sections from 
control and treated animals were processed at the same time and under the same 
conditions. Collected brains were fixed with 4% paraformaldehyde in 0.1 M phosphate 
buffer (pH 7.4) for 3 days, immersed in a 10% sucrose solution for 1 day and in 20% 
sucrose for a further day and subsequently frozen in cooled isopentane and 20-µm-thick 
coronal sections were prepared on a cryostat (Micron, HM 500 M, Walldorf, Germany) for 
striatum and SN as following described. Striatum sections were prepared from A 4.70 mm 
to A 5.70 mm, according to the mouse atlas. For each striatum were collected 15 sections 
by systematic sampling every third section. Five control sections were selected to 
determine optical background of TH and DAT immunostaining for fiber density analysis. 
We analyzed the entire SN from bregma level A2.54 to A4. Coronal sections were made 
and examined for TH-positive cell count were sampled every two sections. In the SNc, cell 
number was determined by using TH and neuron-specific DNA-binding protein (NeuN) 
immunostaining. These two methods were used to explore whether the loss of cells after 
MPTP treatment was due to loss of antigen expression (TH) or to a loss of the cells 
themselves (NeuN). For TH, DAT and NeuN immunostaining floating brain sections were 
used. Following a washing for 5 min in PBS, the sections were preincubated for 30 min in 
blocking buffer consisting of 2.5% normal goat serum and 0.3% Triton X-100 and 0.3% 
hydrogen peroxidase, then washed two times. Sections were subsequently incubated 
overnight at 4°C in PBS/0.3% Triton-X-100 in the presence of the primary antibody and 
1.5% blocking serum. The following antibodies and dilutions were used: mouse polyclonal 
anti-TH and monoclonal anti-NeuN antibodies diluted 1:1,000 and 1:300, respectively 
(AB152 and MAB377 Chemicon, Temecula, CA, USA); rat monoclonal anti-DAT 
antibodies diluted 1:200 (SC32258 Santa Cruz Biotech, CA, USA). Control sections were 
processed without primary antibodies in order to determine optical background of TH and 
DAT immunostaining. After three 5-min washings with PBS, the sections were incubated 
for 1 h with a horseradish peroxidase–streptavidin complex (Vector, Burlingame, CA), 
diluted 1:100 in PBS. After one washing in PBS and one in Tris–HCl buffer (0.1 M pH 
7.4), the peroxidase reaction was developed in the same buffer containing 0.05% 3,3-
diaminobenzidine-4 HCl and 0.003% hydrogen peroxide. The sections were dehydrated 
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and covered with Entellan. The quantification of fibers densities in striatum was performed 
using ImageJ software (http://rsb.info.nih.gov/ij/). The number of TH-positive DA neurons 
of SNc was counted using stereology procedures as described (Aguirre et al. 2008). Every 
mounted section was numbered following the rostrocaudal level corresponding to the 
mouse brain atlas. The total number of cells in different groups was estimated by means of 
the optical fractionator, which combines the optical dissector with the fractionator-
sampling scheme. Volume fraction estimations for TH-positive neurons were computed by 
applying the Cavalieri method based on point counts obtained during the application of the 
optical fractionator. An Olympus BH2 microscope (Olympus, Denmark) was interfaced 
with a computer (DGC systems, Stockholm, Sweden) and a color video camera (CCD-iris, 
Sony, Japan). The CAST-Grid software package (Olympus, Glostrup, Denmark) generated 
sampling frames with a known area and directed the motorized X–Y stage (Lang, 
Huttenberg, Germany), and a microcator (MT12, Heidenheim, Germany), which monitored 
the movements in the Z-axis with a resolution of 0.5 µm. Both sides of the SNc were 
defined using a 4×objective. After having counted the objects (Σ Q-), the total number of 
cells in the nigral region was then estimated as: n = Σ-.fs.fa.fh, where fs is the numerical 
fraction of the section used and considered in the present analysis as fs = 2 since the SN 
sections examined were sampled every two sections, fa is the areal fraction and fh is the 
linear fraction of section thickness. The coefficient of error (CE) for each estimation and 
animal ranged from 0.03 to 0.09. The total CE of each group ranged from 0.02 to 0.06. 
 
Preparation and immunoblotting of different brain regions 
SN and striatum from brains of different experimental groups were dissected under 
stereomicroscopy and frozen in cooled isopentane. The SN was dissected as follows: a 
thick brain coronal section at SN level (A 0,500; A 1,700), according to mouse atlas was 
made using a brain slicer and on this section SN corresponding area, including SNc and 
SNr, was dissected under stereomicroscopy and used for WB analysis by pooling left and 
right SN. Striatum and SN tissue pieces were homogenized in cold buffer containing 50 
mM Tris HCl pH 7.5, 100 mM NaCl, 1 mM DTT, 5% NP-40, 10 µg/ml aprotinin, 10 
µg/ml leupeptin, 0.1 mM phenylmethylsulfonyl fluoride, 100 µM sodium orthovanadate 
(Na3VO4) and 1 mM EDTA (Sigma-Aldrich, St. Louis, MO, USA). The homogenate was 
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left on ice for 30 min and centrifuged at 10,000 × g for 15 min at 4°C to yield supernatant 
fractions that were stored at -80°C until use. To obtain enough material, the two SN were 
pooled from one animals and run together whereas individual striatum was analyzed 
separately. Using SDS-PAGE, 30–40 µg of protein was separated, transferred to 
nitrocellulose membranes (Hybond-C Extra, Amersham), blocked for 1 h in TBST and 5% 
skim milk, and incubated overnight at 4°C with primary antibodies, including anti-DAT, 
anti- TH (1:2,000), anti-SOD2 (1:5,000; Abfrontier, Seoul, Korea) and anti-COX IV 
(diluted 1:5,000, Abcam) antibodies. After washing, the membrane was incubated for 1 h 
at room temperature with peroxidase-conjugated secondary antibodies (diluted 1:5,000) 
and bands were visualized by enhanced chemiluminescence (Amersham ECL). β-actin 
(SC47778 Santa Cruz Biotech, CA, USA 1:6,000) was used as loading control. 
Quantification was performed using ImageJ software (http://rsb.info.nih.gov/ij/). 
 
Cell cultures and immunoblotting 
The SN4741 dopaminergic cell line derived from mouse SN (Son et al. 1999) was 
cultured in Dulbecco’s modified Eagle’s medium/2% fetal calf serum to about 80% 
confluence. Cells were incubated in 96-well Costar plates and treated with different 
concentrations of 1-methyl-4-phenyl pyridinium (MPP+, Sigma) in the absence or presence 
of 5–10 µM RSV. Cell viability was determined using the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (Sigma) assay as described (Korhonen et al. 2001;Sokka 
et al. 2007). Immunoblots were done as described (Kairisalo et al. 2009;Reijonen et al. 
2010) using the following primary antibodies: anti-DAT antibodies diluted 1:200 
(SC32258 Santa Cruz Biotech, CA, USA), SIRT1 (1:2000; Abcam, Cambridge, UK), 
PGC-1α (1:1000; Cell Signaling, Danvers, MA, USA), SOD1 (1:5,000; Santa Cruz 
Biotech), SOD2 (1:30,000; Abfrontier), Trx2 (1:1,000; Abfrontier), Catalase (1:500; 
Abcam), HO-1 (1:500; Stressgen, Ann Arbor, MI, USA), and XIAP (1:5,000; BD 
Biosciences, Franklin Lakes, NJ, USA). Appropriate peroxidase-conjugated antibodies 
(1:2,500, Jackson ImmunoResearch, Biofellows, Helsinki, Finland) were added for 1 h and 
detection was performed using Super Signal West Pico Substrate (Pierce). Quantification 
was performed using ImageJ software. 
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Immunoprecipitation of PGC-1α 
Lysates from control and RSV-treated SN4741 cells were incubated overnight at 4°C 
on a rotary shaker using 10 µg/ml anti-PGC-1α antibodies (Calbiochem, San Diego, CA, 
USA). Immune complexes were bound to Sepharose- A for 2 h at 4°C and recovered by 
centrifugation. Beads were washed three times and the samples resuspended in SDS PAGE 
buffer and subjected to immunoblotting using either anti-PGC-1α antibodies (1:1,000; Cell 
Signaling) or anti-acetylated-lysine antibodies (1:1,000; Cell Signaling). The intensity of 
the bands reveals the degree of acetylation of PGC-1a under different conditions. 
 
Transfection and promotor assays 
SN4741 cells in six-well plates were transfected for 24 h with 0.5 µg of PGC-1α 
promoter constructs linked to luciferase reporter (St-Pierre et al. 2006) using the 
Transfectin reagent followed by treatment with 5–10 µM RSV for 24 h. To control for 
transfection efficiency, 0.02 µg Renilla luciferase pRL-TK was used. Cells were harvested 
after 48 h using Passive Lysis Buffer, and the Renilla and the firefly luciferase activities 
were measured using a luminometer (Promega, Biofellows, Helsinki, Finland) (Kairisalo et 
al. 2009). Results are shown as fold increase in luciferase normalized to Renilla activity.  
 
ROS measurements 
Cells were treated for 24 h with MPTP or RSV. The levels of reactive oxidative 
species (ROS) were measured by loading cells for 15 min with 10 µM dihydroethidium 
(Molecular Probes) followed by examination using fluorescence- activated cell sorter Aria 
(FACS; BD Biosciences) as described earlier (Reijonen et al. 2010;Kairisalo et al. 2007).  
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Quantitative RT-PCR 
Total RNA was extracted from SN of wild-type and PGC1- tg mice using RNeasy 
tissue kit (QIAGEN) followed by cDNA synthesis. Sybergreen (Applied Biosystems) 
realtime quantitative PCR assays were performed on an ABI Prism 7000 Sequence 
Detector essentially as described (Hong et al. 2010). Results show averages of triplicate 
experiments normalized to GAPDH. Primer sequences were:  
SOD2,  
forward (Fw), 5’-GACCCATTGCAAGGAACAA-3’  
and reverse (Rev), 5’-GTAGTAAGCGTGCTCCCACAC-3’; 
COX IV,  
Fw, 5’ TCACTGCGCTCGTTCTGAT -3’  
and Rev, 5’-CGATC GAAAGTATGAGGGATG-3’. 
 
 
High-pressure liquid chromatography (HPLC) 
Dopamine (DA) and 3,4-dihydroxyphenylacetic acid (DOPAC) concentrations in 
mouse striatal tissue were determined essentially as described before (Airavaara et al. 
2006). In brief, the frozen samples were homogenized in 0.5 ml of homogenization 
solution consisting of six parts of 0.2 M HCLO4 and one part of antioxidant solution 
containing oxalic acid in combination with acetic acid and L-cysteine. The homogenates 
were centrifuged at 20,800 × g for 35 min at 4°C. The supernatant was removed to 0.5 ml 
Vivaspin filter concentrators (10,000 MWCO PES; Vivascience AG, Hannover, Germany) 
and centrifuged at 8,600 × g at 4°C for 35 min. Filtrates containing monoamines were 
analyzed using high-pressure liquid chromatography with electrochemical detection. 
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Isolation of mitochondria and measurement of respiratory control 
Mitochondria from wild-type and PGC1-tg mice were prepared essentially as 
described previously for rat liver mitochondria (Speer et al. 2003). In brief, brain tissue 
was excised and minced into pieces in isolation medium containing 10 mM Hepes-K pH 
7.4, 1 mM EGTA, and sufficient sucrose to obtain an osmolarity of 300 mOsm. The brain 
pieces were homogenized and centrifugated at 800 × g for 8 min, and the resulting 
supernatant centrifugated twice at 10,000 × g for 10 min to obtain a mitochondrial pellet 
that was resuspended in 300 µl of isolation medium. All steps were carried out at +4°C and 
mitochondria were used for measurements of membrane potential and respiration within 4 
h. Mitochondrial respiration was measured using a Clarktype electrode (Yellow Springs 
Instruments, USA). Mitochondria were suspended in medium containing 125 mM KCl, 10 
mM Hepes-K pH 7.4, 2 mM MgCl, 1 mM Pi, 100 µM EGTA. Respiration was started by 
the addition of 10 mM malate plus 10 mM glutamate or 10 mM succinate. The respiratory 
control ratio was determined by the addition of aliquots of ADP. Mitochondrial membrane 
potential was measured with the fluorescent dye tetramethylrhodamine (TMRM) using a 
Cary Eclipse Fluorescence Spectrophotometer (Varian, USA) set to operate with excitation 
at 550 nm and emission at 575 nm. The measurement medium was supplemented with 0.5 
µM TMRM. 
 
Quantitative evaluations and statistics 
Quantification of fiber densities was performed using ImageJ software. Immunoblots 
were evaluated by one-way ANOVA with intergroup differences analyzed by Fisher’s 
protected least significant difference (PLSD) test, corrected by Bonferroni’s procedure for 
dependent samples. Statistics of cell viability were performed using Student’s t test 
comparing two groups, and one-way ANOVA followed by Bonferroni’s post hoc test when 
comparing three or more groups. 
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Results 
 
Neuroprotective effects of RSV in dopaminergic neurons in vivo 
The first aim of the present work was to analyze the neuroprotective effect of RSV 
against MPTP-induced dopaminergic cell death in the mouse SNc. The MPTP and RSV 
treatment used, are shown in the scheme of figure 7A. In coronal brain sections, following 
immunohistochemical detection of dopaminergic neurons by tyrosine hydroxylase (TH) 
antibodies, was performed an optical count of TH-positive neurons in the SNc, in order to 
evaluate the neuroprotective effects of RSV treatment. Treatment with MPTP induced a 
44% reduction in the number of dopaminergic neurons in the SNc compared with vehicle 
treated control mice (fig. 7B and 7C). However, co-treatment with 20mg/kg RSV restored 
the number of TH-positive cells to 83% of control (fig. 7B and 7C). The number of NeuN-
stained cells in the SNc in the three experimental groups corresponded to the data obtained 
with TH immunostaining showing that RSV was largely neuroprotective after the MPTP 
insult (fig. 7D). 
MPTP lesion and neuroprotective effect of RSV treatment evaluated by optical count of 
dopaminergic neurons in the SNc 
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In order to further evaluate the neuroprotective effects of RSV treatment we 
examined the density of dopaminergic fibers in the striatum by evaluating TH and DAT 
protein expression levels using western blotting procedure. MPTP treatment led to a 
dramatic reduction (about 63%) of TH protein expression levels in the striatum, as 
compared to control vehicle treated (fig. 8A), but the administration of RSV was able to 
restore the TH levels to 78% of the values observed in vehicle treated control (fig. 8A). 
MPTP lesion and effects of RSV treatment on density of dopaminergic fibers in the 
striatum evaluated by western blotting and immunohistochemistry 
The levels of DAT were also reduced by MPTP treatment to about 25% of controls, 
and RSV also increased this value to about 75% of controls (fig 8B). In control mice, the 
administration of 20 mg/kg RSV alone changed neither the TH nor the DAT protein  levels 
(fig. 8A and 8B). Immunohistochemistry combined with densitometry revealed a 
A 
C 
B 
D 
Fig. 7- RSV protects against MPTP-induced neuronal degeneration in vivo in SNc. 
The neurotoxin MPTP was injected into wild-type mice as described in ‘‘Methods’’. Control 
animals received an equal volume of vehicle. SN was prepared and analyzed further as indicated. 
A: Treatment schedule employing MPTP and RSV is shown with times of injections. B:  
Immunostaining of coronal sections of SNc from control mice (vehicle) and after treatment with 
MPTP or MPTP + RSV. Scale bar 0.5 mm. C Histogram showing the number of TH positive 
neurons in the SNc as determined by stereological analysis. Values are means ± SD, n = 5–7 per 
group. **p\0.01 MPTP versus vehicle and MPTP + RSV versus MPTP. D: Histogram showing the 
number of NeuN positive neurons in the SNc as determined by stereological analysis. Values are 
means ± SD, n = 3–4 per group. **p\0.01 MPTP versus vehicle and MPTP + RSV versus MPTP. 
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significant preservation of TH- and DAT-positive fibers in the striatum of MPTP-treated 
mice after RSV administration (fig. 8C and 8D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A 
C D 
Fig. 8- RSV protects against MPTP-induced neuronal degeneration in vivo in the striatum. 
The neurotoxin MPTP was injected into wild-type mice as described in ‘‘Methods’’. Control 
animals received an equal volume of vehicle. Striatum was prepared and analyzed further as 
indicated. A-B: Immunoblots show declines in TH and in DAT levels induced after MPTP and 
their attenuation by RSV. β-actin was used as control. Values are means ± SD, n = 8–10 per 
group. ***p\0.001 MPTP versus vehicle or RSV, and MPTP + RSV versus MPTP. **p\0.01 
MPTP versus vehicle or RSV, and MPTP + RSV versus MPTP. C: Immunohistochemistry of 
TH and DAT positive neuron endings in striatum (St) was done as described in ‘‘Methods’’. 
Note a partial preservation of dopamine fibers by RSV. D: Densitometric analyses of TH and 
DAT-positive nerve fibers. Values are means ± SD, n = 4. TH, **p\0.01 MPTP versus vehicle 
and p\0.05 MPTP + RSV versus MPTP. DAT, **p\0.01 MPTP versus vehicle and p\0.05 
MPTP + RSV versus MPTP. Scale bar 1 mm. 
B 
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Since RSV is both a free radical scavenger and a potent antioxidant because of its 
ability to promote the activities of a variety of antioxidant enzymes, we evaluated the 
levels of the antioxidant enzyme SOD2 both in the SN than in striatum using western 
blotting procedure. We observed that RSV increased the levels of SOD2 in the SN but not 
in striatum (fig. 9A and 9B). 
RSV treatment enhances antioxidant enzyme SOD2 levels in SN 
 
 
 
 
 
 
 
 
 
 
 
The striking similarity of chemical structure of RSV to the synthetic estrogen 
diethylstilbestrol prompted us to consider the possibility that the extent of neuroprotective 
effects of RSV on MPTP model could be different in male mouse as compared to female 
mouse.  
RSV treatment enhances DAT expression in the striatum of female mouse 
During these experiments was unexpectedly observed that in female mouse, but not 
in male mouse, RSV treatment may lead to a strong increase of dopamine transporter 
(DAT) in the striatum. We treated male and female mice with RSV using daily injections 
of RSV (20 mg/Kg i.p.) for four days and analyzing the brains eight days after the first 
injection of RSV (fig. 10A). Data showed that RSV significantly increased DAT protein 
levels in the striatum of female mice as compared to matched control (fig. 10B). This 
effect of RSV on  DAT levels was also observed in the SN (data not shown). By contrast, 
* 
Fig. 9- RSV treatment enhances antioxidant enzyme SOD2 levels. The 
neurotoxin MPTP was injected into wild-type mice as described in ‘‘Methods’’. 
Control animals received an equal volume of vehicle. SN and striatum were 
prepared and analyzed further as indicated. A: Immunoblot showing increased 
SOD2 levels in SN but not in striatum by RSV. B: Quantification of SN data. 
Values are means ± SD, n = 3. *p\0.05 for RSV versus C. 
 
A B 
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RSV was not able to increase DAT levels in the striatum of male mice (fig 10C). 
Comparing the basic DAT levels between males and females, we did not observe 
significant difference linked to sex (fig. 10D). A time-course study of RSV treatment in 
female mice showed that DAT levels were not yet significantly increased after the last 
injection of RSV, which corresponds to four days from the first injection of RSV (fig. 
10E). In parallel we examined the TH levels in the striatum and found no change of TH 
levels, suggesting a specificity of RSV effect on DAT. TH levels were used as index of 
nigrostriatal innervations and this was not changed by RSV treatment  (fig. 10F).  
 
 
A B C 
D E 
F 
Fig. 10- RSV increases DAT in 
the striatum of female but not in 
male mice. A:Treatment schedule 
employing RSV (20 mg/kg i.p.) is 
shown with times of injections. 
Control mice received equal 
volume of vehicle. Values are 
means ± SD, n = 4. β-Actin was 
used as a control. B: DAT levels 
in the striatum of female mice 
treated with vehicle (control) or 
RSV. Multiple bands present 
reflect the various degree of 
glycosylation of the protein. **P 
< 0.01 for RSV vs control. C: 
DAT levels in the striatum of 
male mice treated with vehicle 
(control) or RSV. D: Basal DAT 
levels in the striatum of male and 
female mice. E: DAT levels in the 
striatum of female mice treated 
with vehicle (control) and RSV 
for four days according the 
injection schedule described in 
results section. F: TH levels in the 
striatum of female mice treated 
with vehicle (control) or with 
RSV. 
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Result obtained by immunoblotting were substantiated using densitometric 
measurements of striatal DAT- immunostained sections, which revealed a significant 
increase in DAT-positive fiber staining in the striatum of female mice treated with RSV 
(fig. 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To verify the involvement of estrogen receptors on RSV-enhanced DAT levels we 
performed a pretreatment of female mice with the selective estrogen receptor antagonist 
ICI 182,780. The dose and scheme of ICI 182,780 and RSV treatment were made as 
follow. Mice were daily pretreated with ICI 182,780 (2 mg/kg s.c.) and after 1,5h were 
treated with RSV (20mg/kg i.p.) and this treatment was repeated for four days and mice 
sacrificed at eighth day from the first injection (fig. 12A). One group of mice received the 
same number of injection with ICI 182,780 alone or RSV alone and an other control group 
of mice received the same number of injections with vehicle. The pretreatment with ICI 
182,780 led to a complete block of RSV effect on DAT protein levels in the striatum as 
compared to control treated with vehicle or with RSV alone (fig.12B). The treatment with 
ICI 182,780 alone did not change the DAT levels in the striatum as compared to control 
treated with vehicle (fig.12B).  
Estrogen receptors mediate RSV effect on DAT  
Fig. 11- RSV increases DAT in the striatum of female but not in male mice. 
Immunohistochemical detection of striatal DAT after RSV. RSV treatment (20 mg/kg i.p.) 
was done as described in results section. Control mice received equal volume of vehicle. 
Values are means ± SD, n= 4. A: representative microphotographs of striatal coronal brain 
sections (AP 5.5 mm) from mice treated with vehicle (control) or RSV. B: histogram shows 
quantitative densitometric values of DAT immunolabelling. ***p < 0.001 for RSV vs control. 
Scale bar: 1 mm. 
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To confirm the observation made in vivo, using the mouse SN4741 cell line, we 
observed that the addition of 10µM RSV for 24h also increased DAT levels in 
dopaminergic cells SN4741 (fig 13A and 13B). Pretreatment with 2 µM of ICI 182,780 
blocked the effect of RSV on DAT levels, as observed in vivo study. 
 
 
 
 
 
 
 
 
 
 
A 
B 
Fig. 13- Effects of antiestrogen 
compound ICI 182,780 on 
RSV-mediated increase of DAT 
in mouse SN4741 
dopaminergic cells. SN4741 
dopaminergic cells were 
stimulated with 10 µM RSV for 
24 h alone or together with  
2µM ICI 182,780. A: Western 
blot of DAT levels. 
Pretreatment with ICI 182,780 
blocked the increase of DAT 
induced by RSV. Typical blot is 
shown and was repeated 3 
times. B: Quantification of 
immunoblots. β-actin was used 
as a control. Values are means 
±SD, n = 3. 
 
A B 
Fig. 12-  Effects of antiestrogen compound ICI 182,780 
on RSV-mediated increase in DAT. Female mice were 
treated with RSV (20 mg/kg i.p.) or vehicle as described in 
results section. Estrogen receptor antagonist, ICI 182,780 
(2 mg/kg s.c.), was injected prior to RSV according to the 
scheme shown in A. B: Western blot analysis of DAT 
levels. Pretreatment with ICI 182,780 blocked the effect of 
RSV-mediated. The treatment with ICI 182,780 alone did 
not change the DAT levels in the striatum as compared to 
control treated with vehicle. β-Actin was used as standard. 
Values are means ±SD, n =4. 
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Mechanisms of RSV-mediated cell protection as studied in dopaminergic cells 
To analyze the mechanisms of RSV action in dopaminergic cells in more detail, we 
studied cultured dopaminergic SN4741 cells that were originally established from mouse 
SN (Son et al. 1999). Treatment of these cells with 1-methyl-4-phenyl pyridinium (MPP+) 
at doses of 400 and 800µM produced a significant loss in cell viability that was 
counteracted by the addition of 5-10 μM RSV (fig. 14A). Since MPP+ is known to produce 
ROS reactive oxidative species and oxidative stress in dopaminergic neurons, we evaluated  
ROS levels in the same models. We observed that MPP+ produced an increase in ROS in 
the SN4741 cells, and this was counteracted by the addition of RSV (fig. 14B). 
Neuroprotective effect of RSV in SN4741 cells exposed to oxidative stress 
 
 
 
Since this antioxidant effect of RSV can also be due to its potential ability to promote 
the activities of a variety of antioxidant enzymes, we next examined in SN4741 cells using 
immunoblotting, the effect of RSV on expression of antioxidant enzymes SOD2 and Trx2, 
two mitochondrial antioxidant enzymes that could be involved in counteracting ROS 
formation. Data showed that RSV elevated SOD2 and Trx2 in the SN4741 cells, especially 
Effect of RSV on expression of antioxidant enzymes SOD2 and Trx2 in SN4741 cells 
A B 
Fig. 14-  Neuroprotective effect of RSV in SN4741 cells exposed to oxidative stress. Cell cultures and treatment 
of mouse SN4741 dopaminergic cells were done as described in ‘‘Methods’’. A: Cells were treated for 48 h with 
MPP+ alone or in conjunction with RSV as indicated. Cell viability was determined using the MTT assay. RSV 
increased cell viability comprised by 400–800 µM MPP+. Values are means ± SD, n = 4. *p\0.05 for MPTP versus 
C, and for MPTP + RSV versus MPTP for both concentrations. B: ROS levels were measured as described in 
‘‘Methods’’. RSV counteracted the increase in ROS in the SN4741 cells induced by MPP+ .Values are means ± 
SD,  
                
  
*** 
         *** 
* * 
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at a dose of 10 µM (fig. 15A and 15B). As control, we  also evaluated the levels of SOD1, 
but have not seen it increased after treatment with RSV (fig. 15A). The increase in SOD2 
by RSV was associated with an enhanced expression of SOD2-mRNA, as evaluated by 
RT-PCR (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to investigate the possible “neuroprotective signaling” involved in the 
mechanism of action of RSV, we evaluated in SN4741 cells the effect of RSV on 
expression of  PGC-1α, a coactivator involved in transcription of mitochondrial genes with 
antioxidant activity.  In particular, the choice of studying the possible involvement of 
PGC-1α in the mechanism of action of RSV was created by the recent evidence that PGC-
1α knockout mice are hypersensitive to the neurotoxin MPTP (St-Pierre et al. 2006) that 
causes degeneration of dopaminergic neurons in mice and in non-human primates. In 
Effect of RSV on expression of PGC-1α in SN4741. 
A B 
Fig. 15- RSV increases the antioxidant enzymes Superoxide Dismutase (SOD2) 
and Thioredoxin 2 (TRX2) in SN4741 cells. Cell cultures and treatment of mouse 
SN4741 dopaminergic cells were done as described in ‘‘Methods’’. A: 
Immunoblots after 24 h treatment with RSV. Note increases in SOD2 and Trx2 by 
RSV but not in SOD1. β-actin was used as control. B: Quantifications. SOD2 and 
Trx2 were increased about fourfold after 10 µM RSV. Values are means ± SD, n = 
3. ***p\0.001 for RSV versus C. 
 
        *** 
        *** 
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additionaly, PGC-1α is regulated by post-transcriptional modifications such as protein 
deacetylation by the mammalian SIRT1 protein which itself can be activated by RSV 
(Feige et al. 2008;Lagouge et al. 2006;Baur and Sinclair 2006). First we found that in 
SN4741 cells RSV increases levels of PGC-1α and SIRT1 by immunoblotting (fig. 16A). 
Moreover, in order to evaluated whether the RSV was able to influence the activation 
status of PGC-1α, we immunoprecipitated for PGC-1α and used an antibody that 
recognizes its acetylated lysines as described in materials and methods. The degree of 
acetylation of PGC-1α was reduced by about 40% (fig 16B) in SN4741 cells after 
treatment with RSV at a dose of 10µM. Thus, RSV has a dual effect on PGC-1α in the 
dopaminergic cells, increasing both the activity and the levels of the protein. In contrast to 
this, the levels of catalase, heme oxygenase, or X-chromosome linked inhibitory apoptosis 
protein (XIAP) were not significantly altered by RSV in the dopaminergic cells (fig. 16C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A B 
C 
Fig. 16- RSV has a dual effect on PGC-1α in the dopaminergic cells SN4741, increasing 
both the activity and the levels of the protein. Cell cultures and treatment of mouse SN4741 
dopaminergic cells were done as described in ‘‘Methods’’. A: Immunoblots after 24 h 
treatment with RSV. Note increases in PGC-1α and SIRT1 by RSV. β-actin was used as 
control. B: Immunoprecipitation of PGC-1α was done as described in ‘‘Methods’’ followed 
by immunoblotting using anti-acetylated-lysine antibodies. Values below show the relative 
ratio of acetylated to total PGC-1α. RSV decreased acetylation of PGC-1α. A representative 
blot is shown and the experiments were repeated three times with similar results. C: 
Immunoblots using specific antibodies revealed no alterations in the indicated proteins in after 
RSV treatment. β-actin was used as control. 
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The increase in PGC-1α levels by RSV was unexpected and promoted us to study 
whether RSV may influence PGC-1α gene expression. To examine this, we employed 
PGC-1α-promoter constructs linked to a luciferase reporter gene (St-Pierre et al. 2006). 
Data showed that the gene activity of the PGC-1a was enhanced by about 80% in the 
SN4741 cells cultured in the presence of 10 µM RSV (fig. 17A).  
Effect of RSV on gene transcription of PGC-1α in SN4741. 
Likewise, in neuronal PC6.3 cells the increase in PGC-1α promoter activity by 10µM 
RSV was about twofold (fig. 17B). Mutation in the MAD box transcription enhancer factor 
(MEF) site in the PGC-1α-promoter reduced the induction in promoter activity brought 
about by RSV (fig. 17A). Mutation in the cAMP response element (Cre)- binding protein 
(CREB) site abolished the RSV-mediated increase and reduced the overall PGC-1α-
promoter activity (fig. 17A). This shows that the activity of the PGC-1 gene in neuronal 
cells is enhanced by RSV and involves the binding of various transcription factors to the 
promoter. 
 
  
Fig. 17- RSV influences gene transcription of 
PGC-1α. A: SN4741 cells were transfected for 24 
h with PGC-1α (PGC) promoter constructs linked 
to a luciferase reporter gene. 10 µM RSV was 
added for an additional 24 h and luciferase 
activity was measured relative to that of Renilla 
as described in ‘‘Methods’’. There was an about 
two fold increase in activity by RSV using the 
intact PGC-1α promoter. No increase was 
observed using constructs having mutations in the 
binding sites for MEF and CRE transcription 
factors. pGL3 is the basic promoter, which 
showed no change after RSV. Values are means ± 
SD, n = 3. ***p ≤ 0.001 for RSV versus C for the 
intact promoter. B: Neuronal PC6.3 cells were 
treated with different concentrations of RSV and 
the activity of the PGC-1α promoter measured as 
above. Values are means ± SD, n = 3. p\0.001 for 
RSV versus C for all concentrations. 
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PGC-1α transgenic mice are protected against MPTP-induced cell degeneration 
The second aim of the present work was to explore the neuroprotective role of PGC-
1α in MPTP mouse model of PD, using transgenic mice overexpressing PGC-1α (PGC1-
tg). PGC-1α is a master regulator of oxidative stress and mitochondrial metabolism. As 
shown in gene-deleted mice decreases in the levels of PGC-1α influences neuronal 
viability and responses to injury in particular parts of the brain (St-Pierre et al. 2006). To 
study whether an overexpression of  PGC-1α may be neuroprotective in vivo, we generated 
transgenic mice expressing PGC-1α in neurons under the control of the Thy-1 promoter 
(fig. 18A). By immunoblots we could show that the levels of PGC-1α were increased in the 
nigrostriatal system in the transgenic compared with controls (fig. 18B). Immunostaining 
using anti-Flag antibodies revealed that the TH-positive dopaminergic neurons expressed 
Flag-PGC-1α that was not observed in controls (fig. 18C). 
Analyses of transgenic mice with overexpression of PGC-1α in brain and in dopaminergic 
neurons. 
 
 
 
 
 
 
 
 
 
 
 
A B
 
C
 
Fig. 18- Analyses of transgenic mice with overexpression of PGC-1α in brain and in 
dopaminergic neurons. A: PGC-1α cDNA containing a Flag-tag was inserted into the 
Thy1 expression cassette and the minigene was used to produce PGC-1α transgenic 
(PGC1) mice. Exons are numbered I–IV. B: Immunoblots of SN and striatum from wild-
type (wt) and PGC1 mice using anti-PGC-1α antibodies as described in ‘‘Methods’’. C: 
Immunostaining of sections from SN using anti-TH and anti-Flag antibodies. Upper 
panels control, wt mice; lower panels PGC1 mice. Note co-expression of Flag-PGC-1α 
with TH in the PGC1 mice but not in controls in the merged picture. Scale bar 50 µm. 
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As PGC-1α is known to influence different transcriptional programs, we studied the 
expression of some antioxidants and mitochondrial proteins involved in cell stress. 
Immunoblots of SN showed that the levels of the mitochondrial antioxidants, SOD2 and 
Trx2 are increased in the SN of PGC-1a transgenic mice compared with wild-type animals 
(fig. 19A). Likewise, the mitochondrial enzyme COXIV was also elevated in the 
transgenic mice compared to controls (fig. 19A). The increase in protein levels in the PGC-
1α transgenic mice was accompanied by an enhanced gene expression, as shown here for 
SOD2 and COX IV using RT-PCR (fig. 19B). This shows that overexpression of PGC-1α 
leads to changes in gene expression for a particular set of proteins in the SN with a 
potentially protective function in cell stress. 
Effects of overexpression of PGC-1α on mitochondrial antioxidants SOD2 and Trx2 and 
on the mitochondrial enzyme COXIV in SN 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
  
A 
B
 
Fig. 19- Overexpression of 
mitochondrial antioxidants 
SOD2 and Trx2 and of the 
mitochondrial enzyme COX 
IV in transgenic mice .  
A: Immunoblots were done as 
described in ‘‘Methods’’ using 
tissue from SN of wild-type 
and PGC1 mice. Protein levels 
of SOD2, Trx2 and COX IV 
were all increased in the PGC1 
mice compared to wt. Left 
panels show typical 
immunoblots and right panels 
are quantification of the data. 
Values are means ± SD, n = 6 
per group. *p\0.05 and 
**p\0.01 for PGC1 mice 
versus wild-type mice. B: 
Quantitative-PCR was done as 
described in ‘‘Methods’’ using 
RNA from SN of wildtype and 
PGC1 mice. Note increased 
expression of SOD2 and COX 
IV. A typical experiment is 
shown and was repeated with 
similar results. 
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To study neuroprotection in the context of dopaminergic neurons, we treated the 
mice with the neurotoxin MPTP. Treatment of wild-type mice with MPTP is known to 
decrease the number of TH-positive neurons in the SNc (Thomas and Beal 2007), and this 
was also evident here as shown in figures 20A and 20B. However, in the PGC-1α 
transgenic mice, the same treatment did not significantly reduce the number of TH-positive 
cells, indicating a robust neuroprotection (fig. 20A and B). Figure 20C shows that the 
number of  NeuN-stained cells in the SNc in the PGC-1α transgenic mice did not change 
after MPTP. In controls, the number of NeuN-positive neurons decreased in SNc as shown 
in figure 7D, and similar results using MPTP have been observed in several studies before. 
The preservation of NeuN-positive cells together with TH-positive neurons supports the 
view that PGC-1α counteracts cell degeneration in SNc after MPTP treatment. 
PGC-1α protects against MPTP-induced neuronal degeneration in vivo in the SN 
 
  
 
  
Fig. 20- PGC-1α protects against MPTP-
induced neuronal degeneration in vivo in 
the SN. The neurotoxin MPTP was 
injected into wild-type (wt) and PGC-1α 
transgenic (PGC1-tg) mice as described in 
‘‘Methods’’. Control animals received an 
equal volume of vehicle. The number of 
TH-positive dopaminergic neurons and 
NeuN-positive cells in the SNc was 
analyzed by using stereology as described 
in ‘‘Methods’’. A: Immunostaining of 
sections from SNc in vehicle and MPTP-
treated wild-type and PGC1-tg mice. 
Scale bar 0.5 mm. B: The number of TH-
positive neurons in the SNc. Values are 
means ± SD, n = 6–12 per group. 
***p\0.001 for MPTP versus vehicle in wt 
animals, and for PGC1-tg +MPTP versus 
WT + MPTP. C: The number of NeuN-
positive neurons in the SNc. Values are 
means ± SD, n = 3–4 per group. 
***p\0.001 MPTP versus vehicle in wt 
animals and for PGC1-tg + MPTP versus 
WT + MPTP. 
A 
B C 
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The neuroprotective role of PGC-1α in transgenic mice observed in the SN, was also 
seen in the striatum. In fact, immunoblots of TH levels in the striatum showed a decrease 
in wild-type but not in PGC-1α transgenic mice (fig. 21). In these experiments, we 
analyzed separately two transgenic mouse lines, PGC11 and PGC12 with similar 
expression of PGC-1α in the brain, and obtained the same results (fig. 21). This shows that 
the transgenic expression of PGC-1α can protect dopaminergic neurons against cell 
degeneration induced by MPTP. 
PGC-1α protects against MPTP-induced neuronal degeneration in vivo in striatum 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig. 21- PGC-1α protects 
against MPTP-induced 
neuronal degeneration in 
vivo in the striatum. The 
neurotoxin MPTP was 
injected into wild-type 
(wt) and PGC-1α 
transgenic (PGC1-tg) 
mice as described in 
‘‘Methods’’. Control 
animals received an equal 
volume of vehicle. 
Immunoblots for TH.  
β-actin was used as 
control. Upper panel 
wild-type mice; middle 
and lower panels two 
different PGC1α 
transgenic mouse lines, 
PGC11 and PGC12 were 
studied. Values are means 
± SD, n = 3–6 for group. 
***p\0.001 MPTP versus 
vehicle in wild-type mice. 
There was no significant 
decrease in TH-positive 
cells in the two transgenic 
mouse lines. 
 
***
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We measured the DA and DOPAC levels in wild-type and PGC-1α transgenic mice 
after MPTP treatment. As expected (Heikkila et al. 1984), MPTP decreased the striatal 
concentration of dopamine and DOPAC and increased the DOPAC/dopamine ratio (fig. 
22A and 22B). The PGC-1α transgenic mice were significantly more resistant to MPTP-
induced neurotoxicity than the wild-type mice as reflected by smaller reduction of 
dopamine and DOPAC (fig. 22A and 22B). In addition, the increase of dopamine/DOPAC 
ratio was lower in the PGC-1α transgenic mice as compared to controls. Taken together, 
this data shows that the overexpression of PGC-1a prevents changes in DA and DOPAC 
striatum induced by MPTP treatment showing a beneficial effect on the functional state of 
the nigrostriatal system in these mice. 
PGC-1α counteracts the decrease in striatal DA and DOPAC levels induced by MPTP 
 
 
 
 
 
 
 
 
 
 
 
  
Fig.22- PGC-1α overexpression 
counteracts the MPTP-induced 
loss of striatal dopamine and 
DOPAC A: Dopamine and B: 
DOPAC levels were determined 
by high-performance liquid 
chromatography as described in 
‘‘Methods’’. The PGC-1α 
transgenic mice (PGC) were 
significantly more resistant to 
MPTP-induced neurotoxicity 
than the wild-type mice as 
reflected by smaller reduction of 
dopamine. Values are means ± 
SE, n = 7–11 per group. 
***p\0.001 for MPTP versus 
vehicle in wild-type animals and 
PGC mice. **p\0.01 for MPTP-
wt animal versus MPTP-PGC1. 
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To explore the mechanisms for neuroprotection, we isolated mitochondria from the 
brains of PGC-1α transgenic and wild-type mice. Measurements of mitochondrial oxygen 
consumption in vitro (Speer et al. 2003) showed an increased rate of respiratory control 
rate in mitochondria from PGC-1α transgenic mice as compared to organelles from wild-
type mice (fig. 23). The relative small difference observed (fig. 23) may be due to the fact 
that mitochondria were isolated from whole brain, thus including also glial cells, which 
have no expression of exogenous PGC-1α driven by the Thy1 construct, being a neuron-
specific promoter (Caroni 1997;Trapp et al. 2003). The higher respiratory control ratio 
observed in brain mitochondria from PGC-1α transgenic mice indicates that the neuronal 
capacity for ATP production is higher in these mice compared to wild-type animals. 
PGC-1α affects the respiration of isolated brain mitochondria 
 
 
  
Fig.23- Studies of mitochondria from wild-
type and PGC-1α transgenic mice. Brain 
mitochondria were prepared as described in 
‘‘Methods’’. Respiration was initiated by the 
addition of 10 mM succinate (succ) followed 
by aliquots of ADP as indicated. Whole 
trace, mitochondria from PGC-1α transgenic 
mice; broken trace, mitochondria from wild-
type mice. The respiratory control ratio was 
1.48 in transgenic and 1.31 in wild-type 
mice. One typical experiment out of three 
mitochondrial preparations is shown. 
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 Discussion 
 
 
Neuroprotective effects of RSV in dopaminergic neurons in vivo 
Treatment with small molecular compounds appears to be an attractive means to 
combat nerve cell degeneration accompanying different brain diseases. In the present work 
using both in vivo and in vitro models, we defined the neuroprotective role of RSV, 
focusing our investigation on neuronal dopaminergic cells. To this end, we first evaluated 
neuroprotective effects of RSV both against MPTP-induced death of SNc in C57BL/6 mice 
and oxidative stress induced neuronal cell death in vitro model (SN4741 cells).  
Subsequently, using in vitro model, we examined the possible mechanisms involved 
on RSV induced neuroprotection. We used MPTP administration to C57BL mice to cause 
a severe Parkinson-like syndrome (Langston and Irwin 1986;Kopin and Markey 
1988;Heikkila et al. 1989;Calon et al. 2001) and, according to previous studies, we showed 
that MPTP administration to C57BL mice leads to the death of DA neurons in the SNc 
(Jakowec et al. 2004) as well as to a dramatically decline of striatal DA and TH levels. The 
dose and scheme of MPTP treatment used have been able to induce about 44% of TH-
positive cells death in the SNc generating a severe condition of neuronal damage. In this 
model we could show a significant neuroprotection of RSV treatment; infact, co-treatment 
with 20 mg/kg RSV restored the number of TH-positive cells to 83% of control by the 
evaluation of dopaminergic cells number in the whole SNc performed both by stereological 
analysis and by double blind optical count. This neuroprotection has also been evaluated 
by measuring both TH and DAT proteins levels in the whole striatum, a parameter largely 
used as analysis of dopaminergic fiber density and therefore as index of dopaminergic 
neurons survival and efficient behavioral recovery in PD animal model. 
While our investigation was in progress, Blanchet et al. reported that the 
administration of a diet containing RSV to adult mice prior to acute treatment with the 
toxin MPTP prevented cellular loss in the SNc in vivo (Blanchet et al. 2008). These data 
are in agreement with the present findings, although the different route of RSV 
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administration. However, there are some previous evidences suggesting that RSV 
treatment could elicit neuroprotective effects on different Parkinsonism models. 
RSV protects dopaminergic neurons in midbrain slice cultures against metabolic and 
oxidative insults (Okawara et al. 2007) or in mice model against MPTP-induced hydroxyl 
radical overloading and neuronal loss (Lu et al. 2008) and in 6-OHDA-induced Parkinson's 
disease rat model (Jin et al. 2008). Taken together these and our data strengthen the idea 
that RSV may be used as  therapy in neurodegenerative diseases of PD. The precise 
mechanisms and targets for RSV in brain tissue are not fully understood at the moment. 
We observed for example that the protection afforded by RSV on fiber density in striatum 
was less than that observed in SN on TH and DAT levels, possibly reflecting a difference 
in the action of RSV in the cell body and in the nerve terminals of TH-positive neurons 
that requires further studies.  
One conclusion that can be drawn here is that the beneficial effect of RSV in 
neuroprotection was related to an increase in SOD2 in brain in vivo, probably contributing 
to the decrease in oxidative stress. In a recent study RSV reduces oxidative stress and cell 
death in neuronal PC6.3 increasing the levels of antioxidants, SOD2 and TRX2, and of X 
chromosome-linked inhibitor of apoptosis protein (Kairisalo et al. 2011). 
  
RSV effect on DAT expression in the striatum of female mouse 
Recent studies have evidenced a neuroprotective role for estrogens in PD (Garcia-
Segura et al. 2001) and in MPTP-mice model or 6-OHDA-lesioned rats (Dluzen 
2000;Ramirez et al. 2003;Murray et al. 2003). It is now recognized that estrogen 
replacement therapy in postmenopausal women reduces the risk of neurodegenerative PD 
diseases and that the antioxidant properties of estrogens contribute to their neuroprotective 
effects (Currie et al. 2004). On the other hand, RSV is a phytoestrogens, which are 
naturally occurring molecules that may exert similar neuroprotective effects as estrogens 
(Esposito et al. 2002).  
The striking similarity of chemical structure of RSV to the synthetic estrogen 
diethylstilbestrol prompted us to consider the possibility that the extent of neuroprotective 
effects of RSV on MPTP model could be different in male mouse as compared to female 
mouse. The results showed that neuroprotective action of RSV against MPTP induced 
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dopaminergic neuron death does not change between male and female. However, during 
the course of these experiments, we have also show unexpectedly that RSV treatment in 
mice leads to a significant increase of DAT expression in the striatum of female but not of 
male mice. This gender difference and the striking similarity of chemical structure of  RSV 
to the synthetic estrogen diethylstilbestrol (Gehm et al. 1997) suggested us to verify the 
possibility that RSV effects on DAT levels may be mediated by estrogen receptors. The 
results obtained both in vivo and in vitro (SN4741 cells) using the selective ER antagonist 
ICI 182,780 showed that estrogen receptors are involved in the up-regulation of DAT in 
the striatum. It has previously been shown using in situ hybridization and 
immunohistochemistry that ERs are present in the SN of adult rats (Shughrue et al. 
1997;Zhang et al. 2002;Creutz and Kritzer 2002;Laflamme et al. 1998). Available data 
suggest that RSV is an agonist for ERs (Gehm et al. 1997) and may bind to both ERα and 
ERβ (Bowers et al. 2000;Mueller et al. 2004;Robb and Stuart 2011;Wu et al. 2008). RSV 
may also activate the non-genomic ER-pathways stimulating intracellular phosphorylation 
events such as mitogen activated protein kinase signaling as shown in vascular endothelial 
cells (Klinge et al. 2005), and phosphatidylinositol-3-kinase signaling activation mediated 
by ERα (Pozo-Guisado et al. 2004). Concerning the binding affinities for RSV on ER it 
was previously shown that RSV activates estrogen-responsive reporter plasmids in the µM 
range (Gehm et al. 1997), and in the present study we therefore used 10 µM to stimulate 
dopaminergic neurons in our vitro model. Pretreatment with ICI 182,780 blocked the effect 
of RSV on DAT levels. Studies of DAT expression in dopaminergic cells showed that 
DAT mRNA is regulated by RSV that suggests a genomic effect of RSV via ICI 182,780-
sensitive ERs. As ICI 182,780 all bind both to ERα and ERβ (Kuiper et al. 1998;el-
Mowafy et al. 2002;Pozo-Guisado et al. 2004;Bowers et al. 2000), is not possible to 
distinguish which estrogen receptor subtype is involved in the RSV action. Previously, it 
was reported that 2,3-bis (4-hydroxyphenyl)-propionitrile, that is an ERβ agonist, mediates 
the estradiol mediated increase of striatal DAT (Le Saux and Di Paolo 2006), suggesting 
that ERβ may be involved in the RSV increase in DAT in striatum. However, RSV has a 
structural similarity mainly to diethylstilbestrol that is an ERα agonist (Le Saux and Di 
Paolo 2006). It remains therefore to be studied which estrogen receptor subtype is involved 
in the RSV action in dopaminergic neurons and in brain in general.  
The involvement of ERs in the regulation of DAT by RSV is in line with previous 
works showing an increase in DAT after estradiol treatment of female mouse (Jourdain et 
al. 2005). It has also been shown that ovariectomy and oestradiol affect DAT and its 
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expression in the rat striatum (Bosse et al. 1997) as well as in SNc (Morissette and Di 
1993). In addition, in vivo imaging studies showed an increase in DAT in the putamen in 
postmenopausal women who received estrogen replacement therapy (Gardiner et al. 2004). 
Dopamine is an important brain neurotransmitter involved in locomotor processes as well 
as cognitive and emotional function. DAT is a key mediator of dopamine uptake and thus 
regulates the amount of dopamine in the synaptic cleft (Gainetdinov and Caron 2003). 
Studies have shown that DAT levels decrease with ageing and this is correlated with a 
deterioration in memory functions (Erixon-Lindroth et al. 2005).  
The present results show that RSV increases DAT levels suggesting that RSV may 
have beneficial effects in ageing and in other cognitive disorders. Estrogen replacement 
therapy in postmenopausal women can reduce the risk of neurodegenerative diseases 
including PD (Dluzen 2000;Garcia-Segura et al. 2001;Currie et al. 2004). However, as 
shown in epidemiological studies there are other risks associated with longterm use of 
estrogens (Hulley and Grady 2004). However, so far the risks and neuroprotective roles of 
estrogen-like polyphenolic compounds, including RSV have not been analyzed in different 
neurodegenerative diseases (Ramassamy 2006).  
 
Mechanisms of RSV-mediated dopaminergic cell protection 
In the present work, following the in vivo evidence of neuroprotective action of 
RSV, we approached the in vitro model (SN4741 cells) in order to identify any potential 
molecular targets of RSV that give account of beneficial effects observed on dopaminergic 
neurons. In the MPTP mouse model of PD the catecholamine-degrading enzyme MAO B 
transforms MPTP into toxic metabolite in the astrocytes, MPP+ and dopaminergic neurons 
are the primary targets of MPP+, which accumulates in mitochondria and interrupts the 
complex I of the respiratory chain and promotes oxygen free radical formation (Adams, Jr. 
et al. 2001;Rajeswari 2006).  
Based on  this oxidative stress mechanism of MPTP induced dopaminergic cell 
death, we observed that treatment of these cells with 1-methyl-4-phenyl pyridinium 
(MPP+) at doses of 400 and 800µM produced a significant loss in cell viability that was 
counteracted by the addition of 5-10 μM RSV. Subsequently, testing the RSV ability to 
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counteract ROS production under oxidative stress, it was possible to show a strong ability 
of RSV to reduce ROS production in both models of cells line used.  
However, more interesting we found that RSV can protect dopaminergic neurons by 
enhancing effects on the expression levels of two antioxidant enzymes (SOD2 and Trx2). 
SOD2 and Trx2 regulate oxidative stress at the level of the mitochondria and these proteins 
are regulated in brain neurons partly by NF-kB activation that is induced by various signals 
including XIAP (Kairisalo et al. 2007;Kairisalo et al. 2011).  
In this study, we observed no change in NF-kB signaling by RSV, suggesting another 
mechanism of action. An obvious candidate for this is SIRT1, which is an NAD+-
dependent deacetylase involved in metabolic regulations and adaptations to stress (Feige et 
al. 2008;Lagouge et al. 2006). SIRT1 activity is linked to neuroprotection in Alzheimer’s 
disease (Qin et al. 2006), and the protein is altered in motor neurons in ALS models (Kim 
et al. 2007). Previous studies have shown that RSV counteracts cell stress and activates 
PGC-1α as well as AMP kinase in neurons (Baur and Sinclair 2006;Dasgupta and 
Milbrandt 2007).  
We observed that RSV increased the levels of SIRT1 in the SN4741 cells and 
activated PGC-1α by reducing acetylation of the protein. Apart from this, RSV increased 
the levels of PGC-1α in the dopaminergic cells probably by affecting gene expression as 
shown using the PGC-1α gene promoter constructs. This data was unexpected, and adds to 
the known biological effects of RSV with a focus particularly on neuronal cells and cell 
protection. Previous studies on RSV indicate that the compound is able to cross the blood–
brain barrier (Baur and Sinclair 2006). RSV was reported to protect against brain damage 
induced by glutamate excitotoxicity, and after brain trauma and ischemia (Baur and 
Sinclair 2006;Della-Morte et al. 2009;Ates et al. 2007).  
The present results obtained with RSV in dopaminergic cells suggest that RSV and 
other small molecular compounds acting via the SIRT1/PGC-1α system may be useful 
agents for neuroprotection in PD. However, the potential use of RSV in different brain 
disorders will require careful analyzes of the kinetics, biological actions, and 
pharmacological profiles of the compound in brain tissue. 
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PGC-1α transgenic mice are protected against MPTP-induced cell degeneration 
On the basis of results revealing an increased levels and activity of PGC-1α after 
treatment with RSV, we have also explored the neuroprotective role of PGC-1α in MPTP 
mouse model of Parkinson’s Disease, using transgenic mice overexpressing  PGC-1α 
(PGC1-tg). Therefore, in the present study, we used the well-characterized promoter, Thy1 
that targets expression of PGC-1α into brain neurons and allows for the study of neuron-
specific changes after brain injuries (Trapp et al. 2003;Wang et al. 2004;Wootz et al. 
2006;Zhu et al. 2007).  
Using PGC-1α transgenic mice, we were able to demonstrate that the overexpression 
of PGC-1α in dopaminergic neurons partially counteracted cell degeneration induced by 
acute MPTP treatments. In PGC-1α transgenic the number of TH-positive neurons in the 
SNc declining after MPTP was significantly protected and the decreases in DA and its 
metabolic DOPAC observed after MPTP were significantly less in these mice compared to 
wild-type ones. Together, this data underscores the importance of PGC-1α signaling in 
neuroprotection of dopaminergic neurons, and adds to previous studies on the role of PGC-
1α in models of neuronal excitotoxicity and cell stress (St-Pierre et al. 2006;Lu et al. 
2010).  
The beneficial effect observed with the PGC-1α transgenic was related to the 
overexpression of the PGC-1α in dopaminergic neurons in the SN. However, the detailed 
mechanism by which PGC-1α is neuroprotective in vivo remains to be studied, including 
the pattern of genes regulated PGC-1α in neurons. We observed that mitochondria isolated 
from PGC-1α transgenic mice had an increased respiratory control ratio compared with 
organelles from wild-type mice, suggesting an increased overall metabolic capacity. 
Whether this is due to increased turnover or dynamics of mitochondria in the PGC-1α 
transgenic mice, remains to be studied. 
 Recently, it was shown that overexpression of PGC-1α in cultured neurons increased 
the mitochondrial capacity and protected cells against mitochondrial loss induced by 
mutant α-synuclein and huntingtin proteins (Wareski et al. 2009). Previous studies on 
PGC-1α expression in rat brain revealed a localization of PGC-1α preferentially in 
GABAergic neurons with a weak immunostaining of neurons in the midbrain (Cowell et al. 
2009). 
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 It is reasonable to assume that the endogenous PGC-1α levels in DA neurons are too 
low to be protective, but that higher levels of PGC-1α can offer neuroprotection. 
Preliminary analyses on mice showed that other neurons than dopaminergic ones were also 
Flag-immunopositive in the SN of PGC-1α transgenic mice. It will be important to analyze 
the nature of these neurons further, and whether they may somehow contribute to the 
neuroprotection observed here. 
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Conclusions 
 
Overall, we have shown that the beneficial effect of RSV was dependent on its 
effects on PGC-1α, a major regulator of cell metabolism and oxidative stress in cells, and 
on mitochondrial antioxidants, SOD2 and Trx2. Therefore, compounds acting, as the RSV, 
on PGC-1α may protect cell degeneration in the SN against oxidative stress and may be 
useful as neuroprotective agents in Parkinson’s Disease and possible in other neurological 
disorders. 
  
dott.sa Melania Olivieri 
54 
Acknowledgements 
 
 
I would like to thank all those persons that during the last three years, in various 
manners, have supported my work.  
Especially thanks to Prof. Natale Belluardo, who introduced me to the world of the 
research, and guide me with professionalism during this beautiful and exciting experience. 
Thanks for his contagious passion for the research that stimulated me to do my work in a 
best way, and for his scientific support that contributed to my professional growth. Thanks 
for all his teachings which, I am sure, will be precious for my future. 
Thanks also to D.ssa Giuseppa Mudò for her essential technical and moral support. Thanks 
for her words that encouraged me when the experiments do not work. 
Thanks to my lab colleagues, Monica (especially), Valentina, Florinda, Maria, for the 
funny moments spent together. 
Finally I want also say thanks to my parents who encouraged me and supported all my 
decisions. 
  
dott.sa Melania Olivieri 
55 
Papers published during doctorate 
 
 
Di Liberto V., Mäkelä J., Korhonen L., Olivieri M.
Involvement of estrogen receptors in the RSV-mediated increase in 
dopamine transporter in human dopaminergic neurons and in striatum of female mice.
, Tselykh T., Mälkiä A., Do Thi H., Belluardo 
N., Lindholm D., Mudò G. 
 
Neuropharmacology. 2011 Oct 24.  
 
Mudò G., Mäkelä J., Di Liberto V., Tselykh T.V., Olivieri M
 
., Piepponen P., Eriksson O., Mälkiä 
A., Bonomo A., Kairisalo M., Aguirre J.A., Korhonen L., Belluardo N., Lindholm D. Transgenic 
expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of 
Parkinson's disease. Cell Mol Life Sci. 2011 Oct 8.  
Frinchi M., Di Liberto V., Olivieri M. FGF-2/FGFR1 
neurotrophic system expression level and its basal activation do not account for the age-dependent 
decline of precursor cell proliferation in the subventricular zone of rat brain.
, Fuxe K., Belluardo N., Mudò G. 
 Brain Res. 2010 Oct 
28;1358:39-45. Epub 2010 Sep 18. 
  
dott.sa Melania Olivieri 
56 
Reference List 
 
Abou-Sleiman P. M., Muqit M. M. and Wood N. W. (2006) Expanding insights of 
mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 7, 207-219. 
Adams J. D., Jr., Chang M. L. and Klaidman L. (2001) Parkinson's disease--redox 
mechanisms. Curr. Med. Chem. 8, 809-814. 
Aguirre J. A., Leo G., Cueto R., Andbjer B., Naylor A., Medhurst A. D., Agnati L. F. and 
Fuxe K. (2008) The novel cyclooxygenase-2 inhibitor GW637185X protects against l-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Neuroreport 19, 657-660. 
Airavaara M., Mijatovic J., Vihavainen T., Piepponen T. P., Saarma M. and Ahtee L. 
(2006) In heterozygous GDNF knockout mice the response of striatal dopaminergic system 
to acute morphine is altered. Synapse 59, 321-329. 
Akao Y., Maruyama W., Yi H., Shamoto-Nagai M., Youdim M. B. and Naoi M. (2002) An 
anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances 
expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci. Lett. 
326, 105-108. 
Albani D., Polito L., Signorini A. and Forloni G. (2010) Neuroprotective properties of 
RSV in different neurodegenerative disorders. Biofactors 36, 370-376. 
Alexandrova M. L. and Bochev P. G. (2005) Oxidative stress during the chronic phase 
after stroke. Free Radic. Biol. Med. 39, 297-316. 
Andersson U. and Scarpulla R. C. (2001) Pgc-1-related coactivator, a novel, serum-
inducible coactivator of nuclear respiratory factor 1-dependent transcription in mammalian 
cells. Mol. Cell Biol. 21, 3738-3749. 
Arvanitoyannis I. S. and Giakoundis A. (2006) Current strategies for dairy waste 
management: a review. Crit Rev. Food Sci. Nutr. 46, 379-390. 
Ates O., Cayli S., Altinoz E., Gurses I., Yucel N., Sener M., Kocak A. and Yologlu S. 
(2007) Neuroprotection by RSV against traumatic brain injury in rats. Mol. Cell Biochem. 
294, 137-144. 
Banerjee R., Starkov A. A., Beal M. F. and Thomas B. (2009) Mitochondrial dysfunction 
in the limelight of Parkinson's disease pathogenesis. Biochim. Biophys. Acta 1792, 651-
663. 
Bar A. O., Amit T. and Youdim M. B. (2004) Contrasting neuroprotective and neurotoxic 
actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. 
Neurosci. Lett. 355, 169-172. 
Baur J. A., Pearson K. J., Price N. L., Jamieson H. A., Lerin C., Kalra A., Prabhu V. V., 
Allard J. S., Lopez-Lluch G., Lewis K., Pistell P. J., Poosala S., Becker K. G., Boss O., 
Gwinn D., Wang M., Ramaswamy S., Fishbein K. W., Spencer R. G., Lakatta E. G., Le C. 
D., Shaw R. J., Navas P., Puigserver P., Ingram D. K., de C. R. and Sinclair D. A. (2006) 
RSV improves health and survival of mice on a high-calorie diet. Nature 444, 337-342. 
dott.sa Melania Olivieri 
57 
Baur J. A. and Sinclair D. A. (2006) Therapeutic potential of RSV: the in vivo evidence. 
Nat. Rev. Drug Discov. 5, 493-506. 
Beal M. F. (2005) Mitochondria take center stage in aging and neurodegeneration. Ann. 
Neurol. 58, 495-505. 
Beal M. F., Palomo T., Kostrzewa R. M. and Archer T. (2000) Neuroprotective and 
neurorestorative strategies for neuronal injury. Neurotox. Res. 2, 71-84. 
Bender A., Krishnan K. J., Morris C. M., Taylor G. A., Reeve A. K., Perry R. H., Jaros E., 
Hersheson J. S., Betts J., Klopstock T., Taylor R. W. and Turnbull D. M. (2006) High 
levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson 
disease. Nat. Genet. 38, 515-517. 
Bezard E., Gerlach I., Moratalla R., Gross C. E. and Jork R. (2006) 5-HT1A receptor 
agonist-mediated protection from MPTP toxicity in mouse and macaque models of 
Parkinson's disease. Neurobiol. Dis. 23, 77-86. 
Blanchet J., Longpre F., Bureau G., Morissette M., DiPaolo T., Bronchti G. and Martinoli 
M. G. (2008) RSV, a red wine polyphenol, protects dopaminergic neurons in MPTP-
treated mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 1243-1250. 
Bonifati V., Rizzu P., van Baren M. J., Schaap O., Breedveld G. J., Krieger E., Dekker M. 
C., Squitieri F., Ibanez P., Joosse M., van Dongen J. W., Vanacore N., van Swieten J. C., 
Brice A., Meco G., van Duijn C. M., Oostra B. A. and Heutink P. (2003) Mutations in the 
DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 
256-259. 
Borgius L. J., Steffensen K. R., Gustafsson J. A. and Treuter E. (2002) Glucocorticoid 
signaling is perturbed by the atypical orphan receptor and corepressor SHP. J. Biol. Chem. 
277, 49761-49766. 
Bosse R., Rivest R. and Di P. T. (1997) Ovariectomy and estradiol treatment affect the 
dopamine transporter and its gene expression in the rat brain. Brain Res. Mol. Brain Res. 
46, 343-346. 
Bowers J. L., Tyulmenkov V. V., Jernigan S. C. and Klinge C. M. (2000) RSV acts as a 
mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141, 3657-
3667. 
Braak H., Braak E., Yilmazer D., Schultz C., de Vos R. A. and Jansen E. N. (1995) Nigral 
and extranigral pathology in Parkinson's disease. J. Neural Transm. Suppl 46, 15-31. 
Bringmann G., God R., Feineis D., Janetzky B. and Reichmann H. (1995a) TaClo as a 
neurotoxic lead: improved synthesis, stereochemical analysis, and inhibition of the 
mitochondrial respiratory chain. J. Neural Transm. Suppl 46, 245-254. 
Bringmann G., God R., Feineis D., Wesemann W., Riederer P., Rausch W. D., Reichmann 
H. and Sontag K. H. (1995b) The TaClo concept: 1-trichloromethyl-1,2,3,4-tetrahydro-
beta-carboline (TaClo), a new toxin for dopaminergic neurons. J. Neural Transm. Suppl 
46, 235-244. 
dott.sa Melania Olivieri 
58 
Brunet A., Sweeney L. B., Sturgill J. F., Chua K. F., Greer P. L., Lin Y., Tran H., Ross S. 
E., Mostoslavsky R., Cohen H. Y., Hu L. S., Cheng H. L., Jedrychowski M. P., Gygi S. P., 
Sinclair D. A., Alt F. W. and Greenberg M. E. (2004) Stress-dependent regulation of 
FOXO transcription factors by the SIRT1 deacetylase. Science 303, 2011-2015. 
Calon F., Lavertu N., Lemieux A. M., Morissette M., Goulet M., Grondin R., Blanchet P. 
J., Bedard P. J. and Di P. T. (2001) Effect of MPTP-induced denervation on basal ganglia 
GABA(B) receptors: correlation with dopamine concentrations and dopamine transporter. 
Synapse 40, 225-234. 
Canto C. and Auwerx J. (2009) PGC-1alpha, SIRT1 and AMPK, an energy sensing 
network that controls energy expenditure. Curr. Opin. Lipidol. 20, 98-105. 
Carlile G. W., Chalmers-Redman R. M., Tatton N. A., Pong A., Borden K. E. and Tatton 
W. G. (2000) Reduced apoptosis after nerve growth factor and serum withdrawal: 
conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol. 
Pharmacol. 57, 2-12. 
Caroni P. (1997) Overexpression of growth-associated proteins in the neurons of adult 
transgenic mice. J. Neurosci. Methods 71, 3-9. 
Chao J., Yu M. S., Ho Y. S., Wang M. and Chang R. C. (2008) Dietary oxyRSV prevents 
parkinsonian mimetic 6-hydroxydopamine neurotoxicity. Free Radic. Biol. Med. 45, 1019-
1026. 
Chaturvedi R. K., Calingasan N. Y., Yang L., Hennessey T., Johri A. and Beal M. F. 
(2010) Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a 
transgenic mouse model of Huntington's disease following chronic energy deprivation. 
Hum. Mol. Genet. 19, 3190-3205. 
Checkoway H., Powers K., Smith-Weller T., Franklin G. M., Longstreth W. T., Jr. and 
Swanson P. D. (2002) Parkinson's disease risks associated with cigarette smoking, alcohol 
consumption, and caffeine intake. Am. J. Epidemiol. 155, 732-738. 
Cleeter M. W., Cooper J. M. and Schapira A. H. (1992) Irreversible inhibition of 
mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical 
involvement. J. Neurochem. 58, 786-789. 
Clow A., Freestone C., Lewis E., Dexter D., Sandler M. and Glover V. (1993) The effect 
of pergolide and MDL 72974 on rat brain CuZn superoxide dismutase. Neurosci. Lett. 164, 
41-43. 
Cowell R. M., Talati P., Blake K. R., Meador-Woodruff J. H. and Russell J. W. (2009) 
Identification of novel targets for PGC-1alpha and histone deacetylase inhibitors in 
neuroblastoma cells. Biochem. Biophys. Res. Commun. 379, 578-582. 
Coyle J. T. and Puttfarcken P. (1993) Oxidative stress, glutamate, and neurodegenerative 
disorders. Science 262, 689-695. 
Creutz L. M. and Kritzer M. F. (2002) Estrogen receptor-beta immunoreactivity in the 
midbrain of adult rats: regional, subregional, and cellular localization in the A10, A9, and 
A8 dopamine cell groups. J. Comp Neurol. 446, 288-300. 
dott.sa Melania Olivieri 
59 
Cui L., Jeong H., Borovecki F., Parkhurst C. N., Tanese N. and Krainc D. (2006) 
Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial 
dysfunction and neurodegeneration. Cell 127, 59-69. 
Currie L. J., Harrison M. B., Trugman J. M., Bennett J. P. and Wooten G. F. (2004) 
Postmenopausal estrogen use affects risk for Parkinson disease. Arch. Neurol. 61, 886-888. 
Dasgupta B. and Milbrandt J. (2007) RSV stimulates AMP kinase activity in neurons. 
Proc. Natl. Acad. Sci. U. S. A 104, 7217-7222. 
Dauer W. and Przedborski S. (2003) Parkinson's disease: mechanisms and models. Neuron 
39, 889-909. 
Davis G. C., Williams A. C., Markey S. P., Ebert M. H., Caine E. D., Reichert C. M. and 
Kopin I. J. (1979) Chronic Parkinsonism secondary to intravenous injection of meperidine 
analogues. Psychiatry Res. 1, 249-254. 
de la Lastra C. A. and Villegas I. (2005) RSV as an anti-inflammatory and anti-aging 
agent: mechanisms and clinical implications. Mol. Nutr. Food Res. 49, 405-430. 
de Lau L. M. and Breteler M. M. (2006) Epidemiology of Parkinson's disease. Lancet 
Neurol. 5, 525-535. 
Della-Morte D., Dave K. R., DeFazio R. A., Bao Y. C., Raval A. P. and Perez-Pinzon M. 
A. (2009) RSV pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 
1-uncoupling protein 2 pathway. Neuroscience 159, 993-1002. 
Dluzen D. E. (2000) Neuroprotective effects of estrogen upon the nigrostriatal 
dopaminergic system. J. Neurocytol. 29, 387-399. 
Drechsel D. A. and Patel M. (2008) Role of reactive oxygen species in the neurotoxicity of 
environmental agents implicated in Parkinson's disease. Free Radic. Biol. Med. 44, 1873-
1886. 
Ebadi M. and Sharma S. K. (2003) Peroxynitrite and mitochondrial dysfunction in the 
pathogenesis of Parkinson's disease. Antioxid. Redox. Signal. 5, 319-335. 
el-Mowafy A. M., Abou-Zeid L. A. and Edafiogho I. (2002) Recognition of RSV by the 
human estrogen receptor-alpha: a molecular modeling approach to understand its 
biological actions. Med. Princ. Pract. 11, 86-92. 
Erixon-Lindroth N., Farde L., Wahlin T. B., Sovago J., Halldin C. and Backman L. (2005) 
The role of the striatal dopamine transporter in cognitive aging. Psychiatry Res. 138, 1-12. 
Esposito E., Rotilio D., Di M., V, Di G. C., Cacchio M. and Algeri S. (2002) A review of 
specific dietary antioxidants and the effects on biochemical mechanisms related to 
neurodegenerative processes. Neurobiol. Aging 23, 719-735. 
Fahn S. (2003) Description of Parkinson's disease as a clinical syndrome. Ann. N. Y. 
Acad. Sci. 991, 1-14. 
Fang Y. Z., Yang S. and Wu G. (2002) Free radicals, antioxidants, and nutrition. Nutrition 
18, 872-879. 
dott.sa Melania Olivieri 
60 
Feige J. N., Lagouge M., Canto C., Strehle A., Houten S. M., Milne J. C., Lambert P. D., 
Mataki C., Elliott P. J. and Auwerx J. (2008) Specific SIRT1 activation mimics low energy 
levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. 
Cell Metab 8, 347-358. 
Finotti N., Castagna L., Moretti A. and Marzatico F. (2000) Reduction of lipid 
peroxidation in different rat brain areas after cabergoline treatment. Pharmacol. Res. 42, 
287-291. 
Floyd R. A., Towner R. A., He T., Hensley K. and Maples K. R. (2011) Translational 
research involving oxidative stress and diseases of aging. Free Radic. Biol. Med. 51, 931-
941. 
Gainetdinov R. R. and Caron M. G. (2003) Monoamine transporters: from genes to 
behavior. Annu. Rev. Pharmacol. Toxicol. 43, 261-284. 
Garcia-Segura L. M., Azcoitia I. and DonCarlos L. L. (2001) Neuroprotection by estradiol. 
Prog. Neurobiol. 63, 29-60. 
Gardiner S. A., Morrison M. F., Mozley P. D., Mozley L. H., Brensinger C., Bilker W., 
Newberg A. and Battistini M. (2004) Pilot study on the effect of estrogen replacement 
therapy on brain dopamine transporter availability in healthy, postmenopausal women. 
Am. J. Geriatr. Psychiatry 12, 621-630. 
Gassen M., Glinka Y., Pinchasi B. and Youdim M. B. (1996) Apomorphine is a highly 
potent free radical scavenger in rat brain mitochondrial fraction. Eur. J. Pharmacol. 308, 
219-225. 
Gehm B. D., McAndrews J. M., Chien P. Y. and Jameson J. L. (1997) RSV, a 
polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. 
Proc. Natl. Acad. Sci. U. S. A 94, 14138-14143. 
Gelinas S. and Martinoli M. G. (2002) Neuroprotective effect of estradiol and 
phytoestrogens on MPP+-induced cytotoxicity in neuronal PC12 cells. J. Neurosci. Res. 
70, 90-96. 
Gerhart-Hines Z., Rodgers J. T., Bare O., Lerin C., Kim S. H., Mostoslavsky R., Alt F. W., 
Wu Z. and Puigserver P. (2007) Metabolic control of muscle mitochondrial function and 
fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J. 26, 1913-1923. 
Gilgun-Sherki Y., Rosenbaum Z., Melamed E. and Offen D. (2002) Antioxidant therapy in 
acute central nervous system injury: current state. Pharmacol. Rev. 54, 271-284. 
Gilman S. C., Bonner M. J. and Pellmar T. C. (1993) Effect of oxidative stress on 
excitatory amino acid release by cerebral cortical synaptosomes. Free Radic. Biol. Med. 
15, 671-675. 
Ginsberg M. D. (2008) Neuroprotection for ischemic stroke: past, present and future. 
Neuropharmacology 55, 363-389. 
Gomez-Vargas M., Nishibayashi-Asanuma S., Asanuma M., Kondo Y., Iwata E. and 
Ogawa N. (1998) Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro 
dott.sa Melania Olivieri 
61 
and inhibits lipid peroxidation in different regions of the rat brain. Brain Res. 790, 202-
208. 
Graham D. G. (1978) Oxidative pathways for catecholamines in the genesis of 
neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14, 633-643. 
Graham D. G., Tiffany S. M., Bell W. R., Jr. and Gutknecht W. F. (1978) Autoxidation 
versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-
hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. 
Mol. Pharmacol. 14, 644-653. 
Greenamyre J. T., MacKenzie G., Peng T. I. and Stephans S. E. (1999) Mitochondrial 
dysfunction in Parkinson's disease. Biochem. Soc. Symp. 66, 85-97. 
Guillot T. S. and Miller G. W. (2009) Protective actions of the vesicular monoamine 
transporter 2 (VMAT2) in monoaminergic neurons. Mol. Neurobiol. 39, 149-170. 
Gupta A., Dawson V. L. and Dawson T. M. (2008) What causes cell death in Parkinson's 
disease? Ann. Neurol. 64 Suppl 2, S3-15. 
Gupta Y. K., Gupta M. and Kohli K. (2003) Neuroprotective role of melatonin in oxidative 
stress vulnerable brain. Indian J. Physiol Pharmacol. 47, 373-386. 
Halliwell B. (2001) Role of free radicals in the neurodegenerative diseases: therapeutic 
implications for antioxidant treatment. Drugs Aging 18, 685-716. 
Halliwell B. (2006) Oxidative stress and neurodegeneration: where are we now? J. 
Neurochem. 97, 1634-1658. 
Halliwell B. and Gutteridge J. M. (1992) Biologically relevant metal ion-dependent 
hydroxyl radical generation. An update. FEBS Lett. 307, 108-112. 
Heikkila R. E., Cabbat F. S., Manzino L. and Duvoisin R. C. (1984) Effects of 1-methyl-4-
phenyl-1,2,5,6-tetrahydropyridine on neostriatal dopamine in mice. Neuropharmacology 
23, 711-713. 
Heikkila R. E., Sieber B. A., Manzino L. and Sonsalla P. K. (1989) Some features of the 
nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) in the mouse. Mol. Chem. Neuropathol. 10, 171-183. 
Ho L., Chen L. H., Wang J., Zhao W., Talcott S. T., Ono K., Teplow D., Humala N., 
Cheng A., Percival S. S., Ferruzzi M., Janle E., Dickstein D. L. and Pasinetti G. M. (2009) 
Heterogeneity in red wine polyphenolic contents differentially influences Alzheimer's 
disease-type neuropathology and cognitive deterioration. J. Alzheimers. Dis. 16, 59-72. 
Hong C., Duit S., Jalonen P., Out R., Scheer L., Sorrentino V., Boyadjian R., Rodenburg 
K. W., Foley E., Korhonen L., Lindholm D., Nimpf J., van Berkel T. J., Tontonoz P. and 
Zelcer N. (2010) The E3 ubiquitin ligase IDOL induces the degradation of the low density 
lipoprotein receptor family members VLDLR and ApoER2. J. Biol. Chem. 285, 19720-
19726. 
Hornykiewicz O. and Kish S. J. (1987) Biochemical pathophysiology of Parkinson's 
disease. Adv. Neurol. 45, 19-34. 
dott.sa Melania Olivieri 
62 
Howitz K. T., Bitterman K. J., Cohen H. Y., Lamming D. W., Lavu S., Wood J. G., Zipkin 
R. E., Chung P., Kisielewski A., Zhang L. L., Scherer B. and Sinclair D. A. (2003) Small 
molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425, 191-
196. 
Hulley S. B. and Grady D. (2004) The WHI estrogen-alone trial--do things look any 
better? JAMA 291, 1769-1771. 
Ienco E. C., Simoncini C., Orsucci D., Petrucci L., Filosto M., Mancuso M. and Siciliano 
G. (2011) May "mitochondrial eve" and mitochondrial haplogroups play a role in 
neurodegeneration and Alzheimer's disease? Int. J. Alzheimers. Dis. 2011, 709061. 
Ignatowicz E. and Baer-Dubowska W. (2001) RSV, a natural chemopreventive agent 
against degenerative diseases. Pol. J. Pharmacol. 53, 557-569. 
Iida M., Miyazaki I., Tanaka K., Kabuto H., Iwata-Ichikawa E. and Ogawa N. (1999) 
Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a 
dopamine agonist. Brain Res. 838, 51-59. 
Jakowec M. W., Nixon K., Hogg E., McNeill T. and Petzinger G. M. (2004) Tyrosine 
hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway. J. 
Neurosci. Res. 76, 539-550. 
Jankovic J. (2002) Levodopa strengths and weaknesses. Neurology 58, S19-S32. 
Jin F., Wu Q., Lu Y. F., Gong Q. H. and Shi J. S. (2008) Neuroprotective effect of RSV on 
6-OHDA-induced Parkinson's disease in rats. Eur. J. Pharmacol. 600, 78-82. 
Jourdain S., Morissette M., Morin N. and Di P. T. (2005) Oestrogens prevent loss of 
dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia 
nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. J. Neuroendocrinol. 17, 509-
517. 
Kairisalo M., Bonomo A., Hyrskyluoto A., Mudo G., Belluardo N., Korhonen L. and 
Lindholm D. (2011) RSV reduces oxidative stress and cell death and increases 
mitochondrial antioxidants and XIAP in PC6.3-cells. Neurosci. Lett. 488, 263-266. 
Kairisalo M., Korhonen L., Blomgren K. and Lindholm D. (2007) X-linked inhibitor of 
apoptosis protein increases mitochondrial antioxidants through NF-kappaB activation. 
Biochem. Biophys. Res. Commun. 364, 138-144. 
Kairisalo M., Korhonen L., Sepp M., Pruunsild P., Kukkonen J. P., Kivinen J., Timmusk 
T., Blomgren K. and Lindholm D. (2009) NF-kappaB-dependent regulation of brain-
derived neurotrophic factor in hippocampal neurons by X-linked inhibitor of apoptosis 
protein. Eur. J. Neurosci. 30, 958-966. 
Keeney P. M., Xie J., Capaldi R. A. and Bennett J. P., Jr. (2006) Parkinson's disease brain 
mitochondrial complex I has oxidatively damaged subunits and is functionally impaired 
and misassembled. J. Neurosci. 26, 5256-5264. 
Kim D., Nguyen M. D., Dobbin M. M., Fischer A., Sananbenesi F., Rodgers J. T., Delalle 
I., Baur J. A., Sui G., Armour S. M., Puigserver P., Sinclair D. A. and Tsai L. H. (2007) 
dott.sa Melania Olivieri 
63 
SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease 
and amyotrophic lateral sclerosis. EMBO J. 26, 3169-3179. 
Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi 
M., Mizuno Y. and Shimizu N. (1998) Mutations in the parkin gene cause autosomal 
recessive juvenile parkinsonism. Nature 392, 605-608. 
Klinge C. M., Blankenship K. A., Risinger K. E., Bhatnagar S., Noisin E. L., 
Sumanasekera W. K., Zhao L., Brey D. M. and Keynton R. S. (2005) RSV and estradiol 
rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial 
cells. J. Biol. Chem. 280, 7460-7468. 
Knutti D., Kaul A. and Kralli A. (2000) A tissue-specific coactivator of steroid receptors, 
identified in a functional genetic screen. Mol. Cell Biol. 20, 2411-2422. 
Kopin I. J. and Markey S. P. (1988) MPTP toxicity: implications for research in 
Parkinson's disease. Annu. Rev. Neurosci. 11, 81-96. 
Korhonen L., Belluardo N. and Lindholm D. (2001) Regulation of X-chromosome-linked 
inhibitor of apoptosis protein in kainic acid-induced neuronal death in the rat hippocampus. 
Mol. Cell Neurosci. 17, 364-372. 
Kraytsberg Y., Kudryavtseva E., McKee A. C., Geula C., Kowall N. W. and Khrapko K. 
(2006) Mitochondrial DNA deletions are abundant and cause functional impairment in 
aged human substantia nigra neurons. Nat. Genet. 38, 518-520. 
Kuiper G. G., Lemmen J. G., Carlsson B., Corton J. C., Safe S. H., van der Saag P. T., van 
der B. B. and Gustafsson J. A. (1998) Interaction of estrogenic chemicals and 
phytoestrogens with estrogen receptor beta. Endocrinology 139, 4252-4263. 
Laflamme N., Nappi R. E., Drolet G., Labrie C. and Rivest S. (1998) Expression and 
neuropeptidergic characterization of estrogen receptors (ERalpha and ERbeta) throughout 
the rat brain: anatomical evidence of distinct roles of each subtype. J. Neurobiol. 36, 357-
378. 
Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq 
N., Milne J., Lambert P., Elliott P., Geny B., Laakso M., Puigserver P. and Auwerx J. 
(2006) RSV improves mitochondrial function and protects against metabolic disease by 
activating SIRT1 and PGC-1alpha. Cell 127, 1109-1122. 
Langston J. W. and Irwin I. (1986) MPTP: current concepts and controversies. Clin. 
Neuropharmacol. 9, 485-507. 
Langston J. W., Irwin I., Langston E. B. and Forno L. S. (1984) 1-Methyl-4-
phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to 
the substantia nigra. Neurosci. Lett. 48, 87-92. 
Larsson N. G., Wang J., Wilhelmsson H., Oldfors A., Rustin P., Lewandoski M., Barsh G. 
S. and Clayton D. A. (1998) Mitochondrial transcription factor A is necessary for mtDNA 
maintenance and embryogenesis in mice. Nat. Genet. 18, 231-236. 
Le Saux M. and Di Paolo T. (2006) Influence of oestrogenic compounds on monoamine 
transporters in rat striatum. J. Neuroendocrinol. 18, 25-32. 
dott.sa Melania Olivieri 
64 
Leonard S. S., Xia C., Jiang B. H., Stinefelt B., Klandorf H., Harris G. K. and Shi X. 
(2003) RSV scavenges reactive oxygen species and effects radical-induced cellular 
responses. Biochem. Biophys. Res. Commun. 309, 1017-1026. 
Lerin C., Rodgers J. T., Kalume D. E., Kim S. H., Pandey A. and Puigserver P. (2006) 
GCN5 acetyltransferase complex controls glucose metabolism through transcriptional 
repression of PGC-1alpha. Cell Metab 3, 429-438. 
Lin J., Tarr P. T., Yang R., Rhee J., Puigserver P., Newgard C. B. and Spiegelman B. M. 
(2003) PGC-1beta in the regulation of hepatic glucose and energy metabolism. J. Biol. 
Chem. 278, 30843-30848. 
Lin J., Wu P. H., Tarr P. T., Lindenberg K. S., St-Pierre J., Zhang C. Y., Mootha V. K., 
Jager S., Vianna C. R., Reznick R. M., Cui L., Manieri M., Donovan M. X., Wu Z., Cooper 
M. P., Fan M. C., Rohas L. M., Zavacki A. M., Cinti S., Shulman G. I., Lowell B. B., 
Krainc D. and Spiegelman B. M. (2004) Defects in adaptive energy metabolism with CNS-
linked hyperactivity in PGC-1alpha null mice. Cell 119, 121-135. 
Liou H. H., Tsai M. C., Chen C. J., Jeng J. S., Chang Y. C., Chen S. Y. and Chen R. C. 
(1997) Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. 
Neurology 48, 1583-1588. 
Liu Y., Fiskum G. and Schubert D. (2002) Generation of reactive oxygen species by the 
mitochondrial electron transport chain. J. Neurochem. 80, 780-787. 
Loh K. P., Huang S. H., De S. R., Tan B. K. and Zhu Y. Z. (2006) Oxidative stress: 
apoptosis in neuronal injury. Curr. Alzheimer Res. 3, 327-337. 
Losa G. A. (2003) RSV modulates apoptosis and oxidation in human blood mononuclear 
cells. Eur. J. Clin. Invest 33, 818-823. 
Lu K. T., Ko M. C., Chen B. Y., Huang J. C., Hsieh C. W., Lee M. C., Chiou R. Y., Wung 
B. S., Peng C. H. and Yang Y. L. (2008) Neuroprotective effects of RSV on MPTP-
induced neuron loss mediated by free radical scavenging. J. Agric. Food Chem. 56, 6910-
6913. 
Lu Z., Xu X., Hu X., Fassett J., Zhu G., Tao Y., Li J., Huang Y., Zhang P., Zhao B. and 
Chen Y. (2010) PGC-1 alpha regulates expression of myocardial mitochondrial 
antioxidants and myocardial oxidative stress after chronic systolic overload. Antioxid. 
Redox. Signal. 13, 1011-1022. 
Martin A. R., Villegas I., Sanchez-Hidalgo M. and de la Lastra C. A. (2006) The effects of 
RSV, a phytoalexin derived from red wines, on chronic inflammation induced in an 
experimentally induced colitis model. Br. J. Pharmacol. 147, 873-885. 
Martinez J. and Moreno J. J. (2000) Effect of RSV, a natural polyphenolic compound, on 
reactive oxygen species and prostaglandin production. Biochem. Pharmacol. 59, 865-870. 
Matthews R. T., Ferrante R. J., Klivenyi P., Yang L., Klein A. M., Mueller G., Kaddurah-
Daouk R. and Beal M. F. (1999) Creatine and cyclocreatine attenuate MPTP neurotoxicity. 
Exp. Neurol. 157, 142-149. 
dott.sa Melania Olivieri 
65 
Mazzio E. A. and Soliman K. F. (2004) Effects of enhancing mitochondrial oxidative 
phosphorylation with reducing equivalents and ubiquinone on 1-methyl-4-
phenylpyridinium toxicity and complex I-IV damage in neuroblastoma cells. Biochem. 
Pharmacol. 67, 1167-1184. 
McGill J. K. and Beal M. F. (2006) PGC-1alpha, a new therapeutic target in Huntington's 
disease? Cell 127, 465-468. 
Miller L. R., Mukherjee S., Ansah T. A. and Das S. K. (2007) Cigarette smoke and 
dopaminergic system. J. Biochem. Mol. Toxicol. 21, 325-335. 
Monsalve M., Wu Z., Adelmant G., Puigserver P., Fan M. and Spiegelman B. M. (2000) 
Direct coupling of transcription and mRNA processing through the thermogenic 
coactivator PGC-1. Mol. Cell 6, 307-316. 
Mootha V. K., Handschin C., Arlow D., Xie X., St Pierre J., Sihag S., Yang W., Altshuler 
D., Puigserver P., Patterson N., Willy P. J., Schulman I. G., Heyman R. A., Lander E. S. 
and Spiegelman B. M. (2004) Erralpha and Gabpa/b specify PGC-1alpha-dependent 
oxidative phosphorylation gene expression that is altered in diabetic muscle. Proc. Natl. 
Acad. Sci. U. S. A 101, 6570-6575. 
Morel I., Lescoat G., Cogrel P., Sergent O., Pasdeloup N., Brissot P., Cillard P. and Cillard 
J. (1993) Antioxidant and iron-chelating activities of the flavonoids catechin, quercetin and 
diosmetin on iron-loaded rat hepatocyte cultures. Biochem. Pharmacol. 45, 13-19. 
Morissette M. and Di P. T. (1993) Effect of chronic estradiol and progesterone treatments 
of ovariectomized rats on brain dopamine uptake sites. J. Neurochem. 60, 1876-1883. 
Mueller S. O., Simon S., Chae K., Metzler M. and Korach K. S. (2004) Phytoestrogens and 
their human metabolites show distinct agonistic and antagonistic properties on estrogen 
receptor alpha (ERalpha) and ERbeta in human cells. Toxicol. Sci. 80, 14-25. 
Murray H. E., Pillai A. V., McArthur S. R., Razvi N., Datla K. P., Dexter D. T. and Gillies 
G. E. (2003) Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the 
nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males 
and females. Neuroscience 116, 213-222. 
Mytilineou C. and Cohen G. (1985) Deprenyl protects dopamine neurons from the 
neurotoxic effect of 1-methyl-4-phenylpyridinium ion. J. Neurochem. 45, 1951-1953. 
Nanjo F., Goto K., Seto R., Suzuki M., Sakai M. and Hara Y. (1996) Scavenging effects of 
tea catechins and their derivatives on 1,1-diphenyl-2-picrylhydrazyl radical. Free Radic. 
Biol. Med. 21, 895-902. 
Nicklas W. J., Vyas I. and Heikkila R. E. (1985) Inhibition of NADH-linked oxidation in 
brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-
methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36, 2503-2508. 
Nicklas W. J., Youngster S. K., Kindt M. V. and Heikkila R. E. (1987) MPTP, MPP+ and 
mitochondrial function. Life Sci. 40, 721-729. 
dott.sa Melania Olivieri 
66 
Oakley A. E., Collingwood J. F., Dobson J., Love G., Perrott H. R., Edwardson J. A., 
Elstner M. and Morris C. M. (2007) Individual dopaminergic neurons show raised iron 
levels in Parkinson disease. Neurology 68, 1820-1825. 
Ogawa N., Tanaka K., Asanuma M., Kawai M., Masumizu T., Kohno M. and Mori A. 
(1994) Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl 
free radicals in vitro. Brain Res. 657, 207-213. 
Okawara M., Katsuki H., Kurimoto E., Shibata H., Kume T. and Akaike A. (2007) RSV 
protects dopaminergic neurons in midbrain slice culture from multiple insults. Biochem. 
Pharmacol. 73, 550-560. 
Olanow C. W. (2002) The role of dopamine agonists in the treatment of early Parkinson's 
disease. Neurology 58, S33-S41. 
Paisan-Ruiz C., Jain S., Evans E. W., Gilks W. P., Simon J., van der Brug M., Lopez de M. 
A., Aparicio S., Gil A. M., Khan N., Johnson J., Martinez J. R., Nicholl D., Carrera I. M., 
Pena A. S., De S. R., Lees A., Marti-Masso J. F., Perez-Tur J., Wood N. W. and Singleton 
A. B. (2004) Cloning of the gene containing mutations that cause PARK8-linked 
Parkinson's disease. Neuron 44, 595-600. 
Palhagen S., Heinonen E., Hagglund J., Kaugesaar T., Maki-Ikola O. and Palm R. (2006) 
Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66, 
1200-1206. 
Pallas M., Casadesus G., Smith M. A., Coto-Montes A., Pelegri C., Vilaplana J. and 
Camins A. (2009) RSV and neurodegenerative diseases: activation of SIRT1 as the 
potential pathway towards neuroprotection. Curr. Neurovasc. Res. 6, 70-81. 
Parker A. J., Arango M., Abderrahmane S., Lambert E., Tourette C., Catoire H. and Neri 
C. (2005) [RSV rescues mutant polyglutamine cytotoxicity in nematode and mammalian 
neurons]. Med. Sci. (Paris) 21, 556-557. 
Pezzuto J. M. (2004) RSV: a whiff that induces a biologically specific tsunami. Cancer 
Biol. Ther. 3, 889-890. 
Phillips M., Cataneo R. N., Greenberg J., Gunawardena R. and Rahbari-Oskoui F. (2003) 
Increased oxidative stress in younger as well as in older humans. Clin. Chim. Acta 328, 83-
86. 
Polymeropoulos M. H., Lavedan C., Leroy E., Ide S. E., Dehejia A., Dutra A., Pike B., 
Root H., Rubenstein J., Boyer R., Stenroos E. S., Chandrasekharappa S., Athanassiadou 
A., Papapetropoulos T., Johnson W. G., Lazzarini A. M., Duvoisin R. C., Di I. G., Golbe 
L. I. and Nussbaum R. L. (1997) Mutation in the alpha-synuclein gene identified in 
families with Parkinson's disease. Science 276, 2045-2047. 
Pozo-Guisado E., Lorenzo-Benayas M. J. and Fernandez-Salguero P. M. (2004) RSV 
modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-
dependent mechanism: relevance in cell proliferation. Int. J. Cancer 109, 167-173. 
Pozzi S., Benedusi V., Maggi A. and Vegeto E. (2006) Estrogen action in neuroprotection 
and brain inflammation. Ann. N. Y. Acad. Sci. 1089, 302-323. 
dott.sa Melania Olivieri 
67 
Przedborski S. (2007) Neuroinflammation and Parkinson's disease. Handb. Clin. Neurol. 
83, 535-551. 
Przedborski S., Jackson-Lewis V., Djaldetti R., Liberatore G., Vila M., Vukosavic S. and 
Almer G. (2000) The parkinsonian toxin MPTP: action and mechanism. Restor. Neurol. 
Neurosci. 16, 135-142. 
Przedborski S., Jackson-Lewis V., Naini A. B., Jakowec M., Petzinger G., Miller R. and 
Akram M. (2001) The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP): a technical review of its utility and safety. J. Neurochem. 76, 1265-1274. 
Puigserver P., Adelmant G., Wu Z., Fan M., Xu J., O'Malley B. and Spiegelman B. M. 
(1999) Activation of PPARgamma coactivator-1 through transcription factor docking. 
Science 286, 1368-1371. 
Puigserver P., Wu Z., Park C. W., Graves R., Wright M. and Spiegelman B. M. (1998) A 
cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92, 
829-839. 
Qin W., Haroutunian V., Katsel P., Cardozo C. P., Ho L., Buxbaum J. D. and Pasinetti G. 
M. (2009) PGC-1alpha expression decreases in the Alzheimer disease brain as a function 
of dementia. Arch. Neurol. 66, 352-361. 
Qin W., Yang T., Ho L., Zhao Z., Wang J., Chen L., Zhao W., Thiyagarajan M., 
MacGrogan D., Rodgers J. T., Puigserver P., Sadoshima J., Deng H., Pedrini S., Gandy S., 
Sauve A. A. and Pasinetti G. M. (2006) Neuronal SIRT1 activation as a novel mechanism 
underlying the prevention of Alzheimer disease amyloid neuropathology by calorie 
restriction. J. Biol. Chem. 281, 21745-21754. 
Rajeswari A. (2006) Curcumin protects mouse brain from oxidative stress caused by 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Eur. Rev. Med. Pharmacol. Sci. 10, 157-161. 
Ramassamy C. (2006) Emerging role of polyphenolic compounds in the treatment of 
neurodegenerative diseases: a review of their intracellular targets. Eur. J. Pharmacol. 545, 
51-64. 
Ramirez A. D., Liu X. and Menniti F. S. (2003) Repeated estradiol treatment prevents 
MPTP-induced dopamine depletion in male mice. Neuroendocrinology 77, 223-231. 
Rasheed A. S., Venkataraman S., Jayaveera K. N., Fazil A. M., Yasodha K. J., Aleem M. 
A., Mohammed M., Khaja Z., Ushasri B., Pradeep H. A. and Ibrahim M. (2010) Evaluation 
of toxicological and antioxidant potential of Nardostachys jatamansi in reversing 
haloperidol-induced catalepsy in rats. Int. J. Gen. Med. 3, 127-136. 
Raval A. P., Lin H. W., Dave K. R., DeFazio R. A., Della M. D., Kim E. J. and Perez-
Pinzon M. A. (2008) RSV and ischemic preconditioning in the brain. Curr. Med. Chem. 
15, 1545-1551. 
Reijonen S., Kukkonen J. P., Hyrskyluoto A., Kivinen J., Kairisalo M., Takei N., Lindholm 
D. and Korhonen L. (2010) Downregulation of NF-kappaB signaling by mutant huntingtin 
proteins induces oxidative stress and cell death. Cell Mol. Life Sci. 67, 1929-1941. 
dott.sa Melania Olivieri 
68 
Robb E. L. and Stuart J. A. (2011) RSV interacts with estrogen receptor-beta to inhibit cell 
replicative growth and enhance stress resistance by upregulating mitochondrial superoxide 
dismutase. Free Radic. Biol. Med. 50, 821-831. 
Rodgers J. T., Lerin C., Haas W., Gygi S. P., Spiegelman B. M. and Puigserver P. (2005) 
Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. 
Nature 434, 113-118. 
Roediger B. and Armati P. J. (2003) Oxidative stress induces axonal beading in cultured 
human brain tissue. Neurobiol. Dis. 13, 222-229. 
Ross J. R., Ramakrishnan H., Porter B. E. and Robinson M. B. (2011) Group I mGluR-
regulated translation of the neuronal glutamate transporter, excitatory amino acid carrier 1. 
J. Neurochem. 117, 812-823. 
Ruderman N. B., Xu X. J., Nelson L., Cacicedo J. M., Saha A. K., Lan F. and Ido Y. 
(2010) AMPK and SIRT1: a long-standing partnership? Am. J. Physiol Endocrinol. Metab 
298, E751-E760. 
Sakata Y., Zhuang H., Kwansa H., Koehler R. C. and Dore S. (2010) RSV protects against 
experimental stroke: putative neuroprotective role of heme oxygenase 1. Exp. Neurol. 224, 
325-329. 
Scarpulla R. C. (2002a) Nuclear activators and coactivators in mammalian mitochondrial 
biogenesis. Biochim. Biophys. Acta 1576, 1-14. 
Scarpulla R. C. (2002b) Transcriptional activators and coactivators in the nuclear control 
of mitochondrial function in mammalian cells. Gene 286, 81-89. 
Schapira A., Bate G. and Kirkpatrick P. (2005) Rasagiline. Nat. Rev. Drug Discov. 4, 625-
626. 
Schapira A. H. (2007) Mitochondrial dysfunction in Parkinson's disease. Cell Death. 
Differ. 14, 1261-1266. 
Schapira A. H. (2008) Progress in neuroprotection in Parkinson's disease. Eur. J. Neurol. 
15 Suppl 1, 5-13. 
Schapira A. H., Agid Y., Barone P., Jenner P., Lemke M. R., Poewe W., Rascol O., 
Reichmann H. and Tolosa E. (2009) Perspectives on recent advances in the understanding 
and treatment of Parkinson's disease. Eur. J. Neurol. 16, 1090-1099. 
Schober A. (2004) Classic toxin-induced animal models of Parkinson's disease: 6-OHDA 
and MPTP. Cell Tissue Res. 318, 215-224. 
Schreiber S. N., Emter R., Hock M. B., Knutti D., Cardenas J., Podvinec M., Oakeley E. J. 
and Kralli A. (2004) The estrogen-related receptor alpha (ERRalpha) functions in 
PPARgamma coactivator 1alpha (PGC-1alpha)-induced mitochondrial biogenesis. Proc. 
Natl. Acad. Sci. U. S. A 101, 6472-6477. 
Sechi G. P., Agnetti V., Piredda M., Canu M., Deserra F., Omar H. A. and Rosati G. 
(1992) Acute and persistent parkinsonism after use of diquat. Neurology 42, 261-263. 
dott.sa Melania Olivieri 
69 
Sevcsik E., Trexler A. J., Dunn J. M. and Rhoades E. (2011) Allostery in a disordered 
protein: oxidative modifications to alpha-synuclein act distally to regulate membrane 
binding. J. Am. Chem. Soc. 133, 7152-7158. 
Shinde S. and Pasupathy K. (2006) Respiratory-chain enzyme activities in isolated 
mitochondria of lymphocytes from patients with Parkinson's disease: preliminary study. 
Neurol. India 54, 390-393. 
Shughrue P. J., Lane M. V. and Merchenthaler I. (1997) Comparative distribution of 
estrogen receptor-alpha and -beta mRNA in the rat central nervous system. J. Comp 
Neurol. 388, 507-525. 
Shulman L. M. (2007) Gender differences in Parkinson's disease. Gend. Med. 4, 8-18. 
Shults C. W. (2006) Lewy bodies. Proc. Natl. Acad. Sci. U. S. A 103, 1661-1668. 
Skaper S. D., Floreani M., Ceccon M., Facci L. and Giusti P. (1999) Excitotoxicity, 
oxidative stress, and the neuroprotective potential of melatonin. Ann. N. Y. Acad. Sci. 890, 
107-118. 
Sokka A. L., Putkonen N., Mudo G., Pryazhnikov E., Reijonen S., Khiroug L., Belluardo 
N., Lindholm D. and Korhonen L. (2007) Endoplasmic reticulum stress inhibition protects 
against excitotoxic neuronal injury in the rat brain. J. Neurosci. 27, 901-908. 
Son J. H., Chun H. S., Joh T. H., Cho S., Conti B. and Lee J. W. (1999) Neuroprotection 
and neuronal differentiation studies using substantia nigra dopaminergic cells derived from 
transgenic mouse embryos. J. Neurosci. 19, 10-20. 
Soobrattee M. A., Neergheen V. S., Luximon-Ramma A., Aruoma O. I. and Bahorun T. 
(2005) Phenolics as potential antioxidant therapeutic agents: mechanism and actions. 
Mutat. Res. 579, 200-213. 
Speer O., Morkunaite-Haimi S., Liobikas J., Franck M., Hensbo L., Linder M. D., 
Kinnunen P. K., Wallimann T. and Eriksson O. (2003) Rapid suppression of mitochondrial 
permeability transition by methylglyoxal. Role of reversible arginine modification. J. Biol. 
Chem. 278, 34757-34763. 
Spina M. B. and Cohen G. (1988) Exposure of striatal [corrected] synaptosomes to L-dopa 
increases levels of oxidized glutathione. J. Pharmacol. Exp. Ther. 247, 502-507. 
St-Pierre J., Drori S., Uldry M., Silvaggi J. M., Rhee J., Jager S., Handschin C., Zheng K., 
Lin J., Yang W., Simon D. K., Bachoo R. and Spiegelman B. M. (2006) Suppression of 
reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. 
Cell 127, 397-408. 
Sulzer D., Bogulavsky J., Larsen K. E., Behr G., Karatekin E., Kleinman M. H., Turro N., 
Krantz D., Edwards R. H., Greene L. A. and Zecca L. (2000) Neuromelanin biosynthesis is 
driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc. 
Natl. Acad. Sci. U. S. A 97, 11869-11874. 
Sun A. Y., Wang Q., Simonyi A. and Sun G. Y. (2010) RSV as a therapeutic agent for 
neurodegenerative diseases. Mol. Neurobiol. 41, 375-383. 
dott.sa Melania Olivieri 
70 
Tatton W. G., Chalmers-Redman R. M., Ju W. J., Mammen M., Carlile G. W., Pong A. W. 
and Tatton N. A. (2002) Propargylamines induce antiapoptotic new protein synthesis in 
serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J. 
Pharmacol. Exp. Ther. 301, 753-764. 
Thomas B. and Beal M. F. (2007) Parkinson's disease. Hum. Mol. Genet. 16 Spec No. 2, 
R183-R194. 
Trapp T., Korhonen L., Besselmann M., Martinez R., Mercer E. A. and Lindholm D. 
(2003) Transgenic mice overexpressing XIAP in neurons show better outcome after 
transient cerebral ischemia. Mol. Cell Neurosci. 23, 302-313. 
Tyynismaa H., Carroll C. J., Raimundo N., Ahola-Erkkila S., Wenz T., Ruhanen H., Guse 
K., Hemminki A., Peltola-Mjosund K. E., Tulkki V., Oresic M., Moraes C. T., Pietilainen 
K., Hovatta I. and Suomalainen A. (2010) Mitochondrial myopathy induces a starvation-
like response. Hum. Mol. Genet. 19, 3948-3958. 
Ubeda A., Montesinos C., Paya M. and Alcaraz M. J. (1993) Iron-reducing and free-
radical-scavenging properties of apomorphine and some related benzylisoquinolines. Free 
Radic. Biol. Med. 15, 159-167. 
Um J. H., Park S. J., Kang H., Yang S., Foretz M., McBurney M. W., Kim M. K., Viollet 
B. and Chung J. H. (2010) AMP-activated protein kinase-deficient mice are resistant to the 
metabolic effects of RSV. Diabetes 59, 554-563. 
Valente E. M., Abou-Sleiman P. M., Caputo V., Muqit M. M., Harvey K., Gispert S., Ali 
Z., Del T. D., Bentivoglio A. R., Healy D. G., Albanese A., Nussbaum R., Gonzalez-
Maldonado R., Deller T., Salvi S., Cortelli P., Gilks W. P., Latchman D. S., Harvey R. J., 
Dallapiccola B., Auburger G. and Wood N. W. (2004) Hereditary early-onset Parkinson's 
disease caused by mutations in PINK1. Science 304, 1158-1160. 
Vila M. and Przedborski S. (2004) Genetic clues to the pathogenesis of Parkinson's 
disease. Nat. Med. 10 Suppl, S58-S62. 
Vingtdeux V., Giliberto L., Zhao H., Chandakkar P., Wu Q., Simon J. E., Janle E. M., 
Lobo J., Ferruzzi M. G., Davies P. and Marambaud P. (2010) AMP-activated protein 
kinase signaling activation by RSV modulates amyloid-beta peptide metabolism. J. Biol. 
Chem. 285, 9100-9113. 
Waldmeier P. C., Boulton A. A., Cools A. R., Kato A. C. and Tatton W. G. (2000) 
Neurorescuing effects of the GAPDH ligand CGP 3466B. J. Neural Transm. Suppl 197-
214. 
Wallberg A. E., Yamamura S., Malik S., Spiegelman B. M. and Roeder R. G. (2003) 
Coordination of p300-mediated chromatin remodeling and TRAP/mediator function 
through coactivator PGC-1alpha. Mol. Cell 12, 1137-1149. 
Wang H. Q. and Takahashi R. (2007) Expanding insights on the involvement of 
endoplasmic reticulum stress in Parkinson's disease. Antioxid. Redox. Signal. 9, 553-561. 
Wang J., Ho L., Zhao Z., Seror I., Humala N., Dickstein D. L., Thiyagarajan M., Percival 
S. S., Talcott S. T. and Pasinetti G. M. (2006) Moderate consumption of Cabernet 
dott.sa Melania Olivieri 
71 
Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease. 
FASEB J. 20, 2313-2320. 
Wang X., Zaidi A., Pal R., Garrett A. S., Braceras R., Chen X. W., Michaelis M. L. and 
Michaelis E. K. (2009) Genomic and biochemical approaches in the discovery of 
mechanisms for selective neuronal vulnerability to oxidative stress. BMC. Neurosci. 10, 
12. 
Wang X., Zhu C., Wang X., Hagberg H., Korhonen L., Sandberg M., Lindholm D. and 
Blomgren K. (2004) X-linked inhibitor of apoptosis (XIAP) protein protects against 
caspase activation and tissue loss after neonatal hypoxia-ischemia. Neurobiol. Dis. 16, 
179-189. 
Wareski P., Vaarmann A., Choubey V., Safiulina D., Liiv J., Kuum M. and Kaasik A. 
(2009) PGC-1{alpha} and PGC-1{beta} regulate mitochondrial density in neurons. J. Biol. 
Chem. 284, 21379-21385. 
Weydt P., Pineda V. V., Torrence A. E., Libby R. T., Satterfield T. F., Lazarowski E. R., 
Gilbert M. L., Morton G. J., Bammler T. K., Strand A. D., Cui L., Beyer R. P., Easley C. 
N., Smith A. C., Krainc D., Luquet S., Sweet I. R., Schwartz M. W. and La Spada A. R. 
(2006) Thermoregulatory and metabolic defects in Huntington's disease transgenic mice 
implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab 4, 349-362. 
Wootz H., Hansson I., Korhonen L. and Lindholm D. (2006) XIAP decreases caspase-12 
cleavage and calpain activity in spinal cord of ALS transgenic mice. Exp. Cell Res. 312, 
1890-1898. 
Wu F., Khan S., Wu Q., Barhoumi R., Burghardt R. and Safe S. (2008) Ligand structure-
dependent activation of estrogen receptor alpha/Sp by estrogens and xenoestrogens. J. 
Steroid Biochem. Mol. Biol. 110, 104-115. 
Wu R. M., Chen R. C. and Chiueh C. C. (2000) Effect of MAO-B inhibitors on MPP+ 
toxicity in Vivo. Ann. N. Y. Acad. Sci. 899, 255-261. 
Wu Z., Puigserver P., Andersson U., Zhang C., Adelmant G., Mootha V., Troy A., Cinti S., 
Lowell B., Scarpulla R. C. and Spiegelman B. M. (1999) Mechanisms controlling 
mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 
98, 115-124. 
Wu Z., Xu Q., Zhang L., Kong D., Ma R. and Wang L. (2009) Protective effect of RSV 
against kainate-induced temporal lobe epilepsy in rats. Neurochem. Res. 34, 1393-1400. 
Yamamoto F., Ohgari Y., Yamaki N., Kitajima S., Shimokawa O., Matsui H. and Taketani 
S. (2007) The role of nitric oxide in delta-aminolevulinic acid (ALA)-induced 
photosensitivity of cancerous cells. Biochem. Biophys. Res. Commun. 353, 541-546. 
Yen G. C., Duh P. D. and Lin C. W. (2003) Effects of RSV and 4-hexylresorcinol on 
hydrogen peroxide-induced oxidative DNA damage in human lymphocytes. Free Radic. 
Res. 37, 509-514. 
Yokoyama H., Takagi S., Watanabe Y., Kato H. and Araki T. (2008) Role of reactive 
nitrogen and reactive oxygen species against MPTP neurotoxicity in mice. J. Neural 
Transm. 115, 831-842. 
dott.sa Melania Olivieri 
72 
Yoshioka M., Tanaka K., Miyazaki I., Fujita N., Higashi Y., Asanuma M. and Ogawa N. 
(2002) The dopamine agonist cabergoline provides neuroprotection by activation of the 
glutathione system and scavenging free radicals. Neurosci. Res. 43, 259-267. 
Youdim M. B., Wadia A., Tatton W. and Weinstock M. (2001) The anti-Parkinson drug 
rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to 
MAO inhibition in cell culture and in vivo. Ann. N. Y. Acad. Sci. 939, 450-458. 
Zhang J. Q., Cai W. Q., Zhou D. S. and Su B. Y. (2002) Distribution and differences of 
estrogen receptor beta immunoreactivity in the brain of adult male and female rats. Brain 
Res. 935, 73-80. 
Zheng B., Liao Z., Locascio J. J., Lesniak K. A., Roderick S. S., Watt M. L., Eklund A. C., 
Zhang-James Y., Kim P. D., Hauser M. A., Grunblatt E., Moran L. B., Mandel S. A., 
Riederer P., Miller R. M., Federoff H. J., Wullner U., Papapetropoulos S., Youdim M. B., 
Cantuti-Castelvetri I., Young A. B., Vance J. M., Davis R. L., Hedreen J. C., Adler C. H., 
Beach T. G., Graeber M. B., Middleton F. A., Rochet J. C. and Scherzer C. R. (2010) 
PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. 
Sci. Transl. Med. 2, 52ra73. 
Zhou C., Huang Y. and Przedborski S. (2008) Oxidative stress in Parkinson's disease: a 
mechanism of pathogenic and therapeutic significance. Ann. N. Y. Acad. Sci. 1147, 93-
104. 
Zhu C., Xu F., Fukuda A., Wang X., Fukuda H., Korhonen L., Hagberg H., Lannering B., 
Nilsson M., Eriksson P. S., Northington F. J., Bjork-Eriksson T., Lindholm D. and 
Blomgren K. (2007) X chromosome-linked inhibitor of apoptosis protein reduces oxidative 
stress after cerebral irradiation or hypoxia-ischemia through up-regulation of mitochondrial 
antioxidants. Eur. J. Neurosci. 26, 3402-3410. 
Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., 
Hulihan M., Uitti R. J., Calne D. B., Stoessl A. J., Pfeiffer R. F., Patenge N., Carbajal I. C., 
Vieregge P., Asmus F., Muller-Myhsok B., Dickson D. W., Meitinger T., Strom T. M., 
Wszolek Z. K. and Gasser T. (2004) Mutations in LRRK2 cause autosomal-dominant 
parkinsonism with pleomorphic pathology. Neuron 44, 601-607. 
Zini R., Morin C., Bertelli A., Bertelli A. A. and Tillement J. P. (1999) Effects of RSV on 
the rat brain respiratory chain. Drugs Exp. Clin. Res. 25, 87-97. 
 
 
 
 
 
